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SUMMARY 
 
Background Melioidosis, caused by the environmental bacterium Burkholderia pseudomallei, is an often-
fatal infectious disease with a high prevalence across tropical areas. Clinical presentation can vary from 
abscess formation to pneumonia and septicaemia. We assessed the global burden of melioidosis, 
expressed in disability-adjusted life years (DALYs), for the year 2015. 
 
Methods A systematic review of the peer-reviewed literature for human melioidosis cases between 1990 
and 2015 was performed. Using a broad search strategy, no language restrictions and combinations of 
search terms, Burkholderia spp. and disease names, all relevant articles were screened on title, abstract, 
and full text. Quantitative data from cases including mortality, age, sex, infectious and post-infectious 
sequelae, antibiotic treatment and symptom duration were extracted. This information was then 
combined with established disability weights and expert panel discussions to construct an incidence-based 
disease model. The disease model was integrated with established global incidence and mortality 
estimates to calculate global melioidosis DALYs. 
 
Findings 2 888 articles were screened, of which 475 eligible studies containing quantitative information 
were retained. Sepsis/septic shock and pneumonia were the most common outcomes, occurring in 18.0% 
(1526/8469), 12.1% (1004/8298) and 35.7% (3633/10175) of patients respectively. The male to female 
ratio of infection was 2:1. We estimate that in 2015, the global burden of melioidosis was 4·6 million DALYs 
(UI 3·2-6·6) or 84·3 per 100 000 people (UI 57·5-120·0). Years of life lost (YLL) accounted for 98·9% (UI 97·7-
99·5) of the total DALYs.  
 
Interpretation Our estimates enable comparison with other tropical diseases which are already recognised 
as neglected and give policy makers the information necessary to reconsider melioidosis as a major 
neglected tropical disease. 
 
Funding European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Research Grant 2018; 
AMC PhD Scholarship; The Netherlands Organisation for Scientific Research (NWO); H2020 Marie 
Skłodowska-Curie Innovative Training Network (MC-ITN) European Sepsis Academy. 
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RESEARCH IN CONTEXT  
 
Evidence before this study  
Previous studies have estimated incidence and mortality rates of melioidosis using regional cohorts. A 
recent study used epidemiological and environmental modelling to estimate the incidence and mortality 
of melioidosis. These global case numbers of incidence and deaths were based on modelling of a 
comprehensive database of 22 338 geographically located records of human and animal melioidosis, 
alongside the presence of environmental B. pseudomallei and are the only known prior global estimates. 
However, attempts to calculate disability-adjusted life years (DALYs) due to melioidosis are lacking, 
hampering comparisons with other neglected tropical diseases (NTDs). Our systematic review of the peer-
reviewed literature for human melioidosis cases between 1990 and 2015, using a broad search strategy 
and combination of search terms, Burkholderia spp. and disease names, without language restrictions, 
returned 2 888 results. Screening abstracts and titles identified 698 reports. Full text screening eliminated 
223 articles that did not meet the inclusion criteria. Therefore 475 studies were included in the data 
synthesis.  
 
Added value of this study  
To our knowledge, this study is the first to provide global estimates of melioidosis in terms of years of life 
lost, years lived with disability, and DALYs at country, regional, and global levels.  As such, it is the most 
comprehensive assessment of the burden of melioidosis so far. Our estimates add important information 
to what is known about melioidosis and the related potential impact of the global diabetes epidemic. Our 
estimates enable comparison with other NTDs which are already recognised as neglected and give policy 
makers the information necessary to reconsider melioidosis in this perspective. 
 
Implications of all the available evidence  
Our results suggest that symptomatic melioidosis infections result in about 4·6 million DALYs annually. In 
comparison, estimates for Intestinal Nematode Infection and Dengue resulted in 4·6 million and 2·9 million 
DALYs respectively. This data has the potential not only to inform public health policy and priority setting 
to address a potentially preventable and debilitating disease, but should also lead to the official 
recognition of melioidosis as a major NTD.  
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INTRODUCTION  
 
Burkholderia pseudomallei is the environmental Gram-negative bacillus that causes melioidosis; a disease 
characterized by sepsis, abscess formation and significant case-fatality (10-50%) even when appropriately 
treated.1-3 First recognised in 1911,3 melioidosis primarily affects individuals with altered immune function 
and those in regular contact with soil and ground water. Southeast Asia and northern-Australia are the 
major endemic regions, although melioidosis appears to be ubiquitous across the tropics.4 Diagnosis can 
be difficult due to its diverse clinical manifestations and the inadequacy of conventional bacterial 
identification methods.5 Additionally, a large proportion of cases may be missed due to paucity of 
diagnostic facilities.6,7 A recent modelling study that mapped documented human and animal cases as well 
as the presence of environmental B. pseudomallei estimated the global incidence to be 165 000 (68 000-
412 000) human melioidosis cases per year worldwide, of which 89 000 (36 000-227 000) people die,4 most 
of whom are in low to middle-income countries (LMIC). Despite this, melioidosis is currently not included 
in the neglected tropical diseases (NTDs) listed by the World Health Organization (WHO).3  
 
The disparity between the number of reported cases and estimated number of actual cases stems from 
under-recognition and under-reporting of melioidosis.4 Symptomatic melioidosis infections are usually 
acute, but the broad range of clinical manifestations, from localised skin lesions to septic shock, hinders 
recogition.8 Chronic melioidosis, defined as symptoms that last longer than two months, is present in 
approximately 11% of cases.2 Unlike the incidence of some NTD,9 the reported incidence of melioidosis is 
increasing, partly due to increasing awareness amongst physicians and researchers and the expansion of 
diagnostic services, although there may also be genuine increases in incidence.10 Melioidosis often results 
in intensive care admission and requires prolonged antibiotic therapy (up to 6 months),3 which also makes 
the treatment and consequences of this disease costly. 
 
A metric that can be used to summarise morbidity, disability and mortality into a single index is the 
disability-adjusted life year (DALY). The DALY provides additional information to incidence/prevalence and 
mortality data, allowing for comparison of disease burden across populations and diseases.11 DALYs of 
some NTDs have been estimated previously, which showed the relative importance of these diseases 
compared to other causes of ill health, although this has never been done for melioidosis.9 
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The aim of our study was to quantify for the first time the global burden of melioidosis in terms of DALYs. 
By combining the modelled estimates of the global incidence and mortality of melioidosis4 with a 
systematic review of the published literature on its clinical impact, we calculated the global DALYs for 
melioidosis for the year 2015 by age, sex and country. In addition, we examined the relationship between 
melioidosis burden and the Socio-demographic Index (SDI),12 a composite indicator based on income, 
education, and fertility. Furthermore, we analysed the relationship between Healthcare Access and Quality 
(HAQ) Index,13 a score developed by the Global Burden of Disease (GBD) studies, which can be used as a 
robust method for tracking universal health access. By further elaborating the proportion of cases 
presenting with known risk factors (i.e., diabetes, chronic liver disease or alcohol abuse, chronic renal 
failure, and chronic lung disease), we provide crucial input into melioidosis control policies. Our estimation 
of the global burden of melioidosis is in accordance with the GATHER guidelines (webappendix pp 11-12).14  
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METHODS 
 
Study design and procedures 
We systematically searched Medline, Embase, WHO Global Health Library, and the database on 
melioidosis.info without language restriction, for reports of human melioidosis published between Jan 1, 
1990 and Dec 31, 2015. A broad search strategy and combination of test searches and terms, Burkholderia 
spp. and disease names were used to capture a range of outcomes associated with melioidosis 
(webappendix pp 3-4). To foster data quality, we only included culture-confirmed cases of melioidosis. 
Two independent reviewers (JS, HV) screened titles and abstracts for relevance, and any disagreement 
about eligibility between reviewers was resolved by discussion and ultimately a third author (EB). The 
search of published works and data extraction was done by EB, HV and JS (webappendix pp 7-8). Due to 
the absence of data on post-infectious sequelae in the initial systematic review, an expert opinion-guided 
supplementary search was conducted (webappendix pp 3-4). We conducted the review according to 
guidance from the Cochrane handbook of interventions and reported the systematic review according to 
PRISMA guidelines where applicable (webappendix pp 9-10). This study was registered in PROSPERO 
(CRD42018106372). 
 
Synthesis of global epidemiological data is used to quantify disease burden using the DALY metric, which 
is composed of time lost due to morbidity (YLD = years lived with disability) and time lost due to mortality 
(YLL = years of life lost). One DALY is equivalent to 1 year of healthy life lost.11 An incidence-based disease 
model of melioidosis disease states (sequelae) and post-infectious sequelae, was developed to 
quantitatively assess the melioidosis disease burden (Figure 1).15  
 
Disability weights (DWs), are weight factors reflecting severity of disease, ranging from 0 (perfect health) 
to 1 (equivalent to death). For this study, the DWs for health outcomes from the GBD study were adopted 
if possible,20 otherwise a new DW for ‘intensive care admission’ was used from a European study involving 
30,660 responses.21 When exact matches were not available, proxy disease outcomes were identified 
based on best matching description and expert agreement (Table 1). See webappendix pp 13 for our 
analytical model flowchart for DALY calculation and melioidosis database development. 
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Based on a combination of literature, clinical expertise and consensus, we divided melioidosis into disease 
states (or sequelae) (Table 1): (1) septic shock, (2) sepsis, (3) pneumonia, (4) central nervous system 
infection (CNS), (5) intra-abdominal abscess, (6) musculoskeletal infection (MSK), (7) urinary tract infection 
(UTI), (8) parotitis (including lymphadenitis), (9) skin and soft tissue infection (SSTI), and (10) other (mainly 
pericarditis and mycotic aneurysms). Although we modelled individual outcomes/sequelae, overlap was 
allowed; thus implicitly, multifocal or disseminated cases of infection were also included. Oral antibiotic 
treatment was considered as an additional health state in non-fatal cases. Post-infectious sequelae data 
for melioidosis were also extracted from additional literature searches for sepsis and septic shock,16 
ongoing neurologic impairment,17 and ongoing MSK problems,18,19 which were validated against expert 
opinion. These models allowed quantification of global burden of melioidosis as expressed in DALYs. Due 
to the scarceness of good quality epidemiological data on melioidosis and to reduce duplication of effort, 
we extracted mortality and incidence estimates from a recent modelling study4 and estimated DALYs 
based on the 2015 estimates of the UN World Population Prospects 2017 revision 
(https://population.un.org/wpp).  
 
In addition, we established the age and sex distribution of melioidosis cases per WHO region based on the 
data resulting from our systematic review (Figure 2). We used the same age-sex distribution for all 
countries within the same region. The case definition of melioidosis was isolation of B. pseudomallei from 
any site, ensuring capture of all types of culture-positive melioidosis, including localised and disseminated 
forms. All included cases represented symptomatic infection. Relapse or recrudescence of infection were 
counted as separate cases.  
 
YLDs were calculated for the main melioidosis symptoms (i.e., sepsis, pneumonia), as well as for antibiotic 
treatment and lifelong post-infectious sequelae among surviving cases. Our systematic review provided 
data on the health state durations and on the probabilities of developing the considered symptoms. All 
surviving patients were assumed to receive antibiotic treatment, while the probabilities of developing 
post-infectious sequelae among surviving cases were derived from the literature.16-19 Disability weights 
were derived from the Global Burden of Disease study.20 YLLs, YLDs and post-infectious sequelae were 
calculated using the WHO standard life expectancy table,23 while the GBD standard life expectancy table12 
was used in a scenario analysis. The case data from our systematic review were used to derive an age and 
sex distribution of incident cases and deaths by WHO region. DALYs were calculated by country, and 
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subsequently aggregated at regional and global level. Based on our case data, we also calculated the 
proportion of patients who presented with known melioidosis risk factors, i.e., diabetes, chronic liver 
disease or alcohol abuse, chronic renal failure and chronic lung disease.  
 
Parameter uncertainty was quantified and propagated using 10,000 Monte Carlo simulations 
(webappendix pp 18). The resulting uncertainty distributions were summarised by their mean and a 95% 
uncertainty interval (UI) defined as the distribution’s 2·5th and 97·5th percentile. In subsequent analyses, 
we used linear regressions to analyse the associations between the country-specific log-transformed 
melioidosis DALYs and the countries’ SDI scores12 and HAQ indices13 for 2015 (webappendix pp 15). We 
also quantified the association between global DALYs for melioidosis and other NTDs, and their respective 
levels of funding according to http://www.who.int/research-observatory.24 All analyses were performed 
in R 3.5.1 (R Core Team, 2018). 
 
Role of funding source  
The study funders had no role in the study design, data collection, data analysis, data interpretation, or 
writing of the final report. The corresponding author had full access to all the data in the study and had 
final responsibility for decision to submit for publication. 
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RESULTS 
 
Our systematic review identified 2 888 studies, of which 475 were included in the quantitative analyses 
(webappendix pp 6). In total, 11 767 cases from five of six WHO regions were available (webappendix pp 
14). The incidence age and sex distribution is largely similar to the mortality age and sex distribution (Figure 
2), and also to DALY age and sex distribution, given that the majority of patients die during the acute stage 
of their illness. However, regional differences were observed with respect to the median age of incidence, 
which was 36 years in the American region (AMR), compared to 50, 47, 49 and 60 years for the South-East 
Asian region (SEAR), Western-Pacific region (WPR), African region (AFR) and Eastern Mediterranean region 
(EMR) respectively (webappendix pp 19-21). Below the age of 14, the age-sex distribution of melioidosis 
incidence was similar across regions, whereas for 14 years and older the male to female incidence and 
mortality of melioidosis was 2:1 (Figure 2). 
 
Of all melioidosis cases identified, 88·4% (4589/5194) were acute and 11·7% (605/5194) chronic. Sepsis, 
intra-abdominal abscess, and pneumonia were the most common outcomes, occurring in 18·0% (UI 17·2-
18·9), 18·3% (UI 17·5-19·1) and 35·7% (UI 34·9-36·6) of patients respectively. In total, 12·6% (UI 12·0-13·3) 
presented with SSTI, 12·1% (UI 11·4-12·8) with septic shock, 8·2% (UI 7·7-8·7) with MSK infections, 6·7% 
(UI 6·2-7·2) developed UTI, 2·6% (UI 2·3-2·9) other infections such as pericarditis and mycotic aneurysms, 
2·3% (UI 2·0-2·6) parotitis and 1·6% (UI 1·4-1·9) developed CNS infections (webappendix pp 22-23). Chronic 
post-infectious sequelae, most notably general malaise/weakness, cognitive impairment and readmissions 
predicted to occur in 16·7% (UI 0·5-52·1) of septic patients,16 ongoing functional and cognitive impairment 
in 36·2% (UI 24·4-48·8) of CNS infection patients,17 and ongoing arthritic symptoms and mobility problems 
in 40·7% (UI 34·1-47·5) of MSK infection patients (webappendix pp 22-23).18,19 Septic shock had the 
shortest mean duration of symptoms prior to admission of 8·2 d (sd 8·4 d) and hospitalization of 14·5 d (sd 
15·8 d). Pneumonia had a mean duration of symptoms prior to admission of 10·9 (sd 10·6) and 
hospitalization of 21·4 (sd 17·3) days. MSK and intra-abdominal abscess had the longest mean duration of 
symptoms prior to admission of 63·3 (sd 168·8) and 67·4 (sd 206·4) respectively which also coincides with 
longest mean number of days hospitalized, 33·9 (sd 56·2) and 32·9 (sd 60·2) days respectively. The mean 
duration of consolidation therapy was 129·5 days (sd 48·0). 
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Overall, by integrating the predicted incidence and mortality data with our disease model,4 we estimated 
that melioidosis was responsible for 4 635 636 DALYS (UI 3 164 157-6 602 075) in 2015,  corresponding to 
84·3 DALYs (UI 57·5-120·0) per 100 000. YLLs accounted for 98·9% (UI 97·8-99·5) of the total DALYs. The 
highest total burden occurred in India, where melioidosis resulted in 1 596 733 DALYs (UI (503 727-3 320 
277), while Cambodia had the highest DALY per 100 000 people (with 414·6 DALYs per 100 000; UI 111·9-
919·4). In 2015, India, Bangladesh, Vietnam, Nigeria and Indonesia combined made up 70·5% (UI 57·7-
80·9) of total melioidosis DALY burden (3 307 178 DALYs; UI 1 892 971-5 251 783). SEAR carried the highest 
burden of DALYs (158·1 per 100 000 people; UI 88·3-256·0), followed by AFR (84·1; UI 43·4-152·4) and then 
WPR (45·6; UI 27·7-69·5) (Figure 3; Table 2). 
 
YLDs were responsible for 1·1% (50 541·7 UI 22 778·2-97 825·4) of the total melioidosis DALYs. With post-
infectious sequelae contributing most to the YLDs (86·8%; UI 70·2-95·2), followed by symptoms 9·9% (UI 
3·0-25·5) and oral antibiotic treatment 3·4% (UI 1·0-8·0). The proportion of patients with melioidosis also 
having underlying diabetes or newly diagnosed hyperglycaemia was 46·1% (UI 45·2-47·0), with chronic 
kidney disease, chronic liver disease or alcohol abuse, and chronic lung disease representing 9·3% (UI 8·8-
9·8), 7·4% (UI 6·9-7·9) and 3·4% (UI 3·0-3·7) respectively (webappendix pp 22-23). As a proportion of DALYs, 
diabetes alone accounted for 2 137 433·3 (UI 1 459 182·0-3 046 177·1). Total DALYs per country showed a 
negative association with both SDI and HAQ Index (webappendix pp 28, Figure S6), reinforcing the known 
trend of improving outcomes with better access to healthcare and improved education. These associations 
also help to identify those countries with discrepancies in access to healthcare and high DALYs, such as 
Thailand and Singapore. Additionally, the Philippines, Indonesia and Thailand, despite having higher SDI, 
display a high burden of melioidosis (webappendix pp 28-31). For example, Thailand, despite having good 
access to healthcare (70·8 HAQ Index) and good socio-demographic development (0·705 SDI), still shows 
a high melioidosis DALY burden (212·6 per 100 000 people; UI 72·4-430·1). The scenario analysis using the 
GBD life expectancy tables resulted in 4 093 110 (UI 2 790 743-5 826 117) DALYs, 11·7% lower than the 
result using the WHO life expectancy table (webappendix pp 25-27, Table S6). 
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DISCUSSION 
 
Our study, using a systematic review and data synthesis, is the first to provide estimates of the global 
burden of melioidosis in terms of DALYs. We estimated that in 2015 the global burden of melioidosis was 
4·6 million DALYs (UI 3·2-6·6 million), corresponding to 84·3 DALYs (UI 57·5-120·0) per 100 000 people. 
YLLs accounted for 98·9% (UI 97·7%-99·5%) of the total DALYs. 
 
Our study provides worldwide estimates, including regions of South Asia, South America, and Africa where 
the burden of melioidosis has been under-appreciated and possibly misallocated to other febrile illnesses 
such as malaria and tuberculosis.6,7 Putting this into context, the global burden of melioidosis as expressed 
in DALYs (4·64 million) is higher than leptospirosis (2·90 million), dengue (2·86 million), schistosomiasis 
(2·63 million), lymphatic filariasis (1·24 million) and leishmaniasis (1·06 million) (webappendix pp 32-33). 
The burden per million DALYs of melioidosis compared to the estimates of officially recognized neglected 
and re-emerging tropical diseases estimated by the WHO and amount invested globally in research and 
development is showed in webappendix pp 32-33 (Figure S7). This shows that there is no clear association 
between DALY burden and level of global investment (p = 0·892), which we feel should prompt re-
evaluation of how resources are allocated for NTDs. 
 
Our scenario analysis which represents differences between WHO and GBD life expectancy tables alone, 
resulted in 11·7% higher DALY estimates (webappendix pp 25-27). Additionally, an incidence-based 
approach was preferred as it has been shown to provide a more reliable metric for infectious diseases,15,25 
and we restricted our systematic review to culture confirmed cases only to limit bias. 
The results of our systematic review also showed that incidence, mortality, and DALYs from melioidosis 
were about twice as high for men as for women, a finding similar to that in tuberculosis.26 As with 
tuberculosis, several explanations have been given for the gender difference in melioidosis risk; including 
differential occupational exposures, differential access to health care, differential exposure to risk factors, 
and genetic variation.3,26 This interplay of risk factors and age-sex distribution of melioidosis cases, deaths, 
and DALYs has strategic implications for melioidosis control programmes by allowing targeting of high risk 
groups. 
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The gold-standard for diagnosis of melioidosis is culture; therefore, we limited our case definition to only 
culture-proven melioidosis. Due to the low sensitivity and specificity of currently used serological tests,3 
we decided to take this more conservative approach. However, the estimated sensitivity of culture in 
melioidosis is only 60·2%.3 This means that there is an opportunity for future studies using more robust 
serological tests than those that are currently available to provide even better estimates of the true burden 
of melioidosis that can be incorporated into DALY calculations. 
 
Globally, in 2015, the top four risk factors for melioidosis (diabetes, chronic liver disease or alcohol abuse, 
chronic renal disease and chronic lung disease) were present in 46·1%, 7·4%, 9·3%, and 3·4% of melioidosis 
cases respectively (webappendix pp 24). Thus, efforts to prevent these risk factors or provide a cost-
effective vaccine targeted ‘at-risk’ groups such as diabetic rice farmers, could have substantial collateral 
impact on the burden of melioidosis. Interestingly, in our analysis HIV, occurring in less than 1%, does not 
appear to be associated with acquiring melioidosis, which is consistent with evidence from previous 
smaller cohorts.3,27 As many countries go through demographic and epidemiological transitions, 
particularly those in LMICs are poised to suffer the double burden of melioidosis and diabetes.28 Global 
YLLs for diabetes have gone from rank 27 to rank 15 between 1990 and 2015, a 45·3% increase.29 Indeed, 
diabetes alone carries a 12 times relative risk of acquiring melioidosis in endemic regions3,10 and with the 
global diabetes pandemic, there is potential for catastrophic increase in melioidosis burden, with LMIC 
facing the brunt.  
 
Our study has several limitations. First, globally reliable incidence and mortality data for calculating the 
global burden of melioidosis were scarce. Therefore, the global case numbers of incidence and deaths 
were based on modelling of a comprehensive database of 22 338 geographically located records of human 
and animal melioidosis, alongside the presence of environmental B. pseudomallei.4 Given the 
imperfections in data sources, we believe our methodology of integrating existing information and 
knowledge through a systematic literature review and data synthesis provides a more robust assessment 
of melioidosis epidemiology than has been done so far. Second, we did not include all possible sequelae 
in our outcome tree designed to calculate DALYs, because of paucity of data particularly on the rarest 
sequelae. Specific DWs were not available for most of the disease outcomes (for example septic shock, 
sepsis, CNS infection, intra-abdominal abscess, MSK infection, UTI, parotitis, SSTI, and post-infectious 
sequelae amongst others) and proxy health states were decided based on the best matching descriptions 
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and expert opinion. Further studies generating DWs should include those disease outcomes in their future 
surveys. In particular, the lack of a DW for sepsis,30 a critical illness with a high disability, is a significant 
handicap for such work and highlights the need for better DWs to be developed in future. We believe that 
it is insufficient to use the severe acute infectious disease disability weightDW30 for sepsis given the 
mounting evidence of prolonged disability and involvement in organ dysfunction in sepsis (as per 3·0 
guidelines definition).31 Third, outcomes of post-melioidosis sequelae, such as those following 
sepsis/septic shock, CNS infection and MSK infection, had very limited data available, and were therefore 
extracted through review of additional literature.16-19 These post-infectious sequelae were modelled on 
the remaining life expectancy of survivors and a shortened life expectancy was not accounted for. 
Although YLDs did not appear to have a significant contribution to overall DALYs in melioidosis, we only 
accounted for a limited number of post-infectious sequelae, and given that 86·8% (UI 70·2-95·2) of YLDs 
are due to the post-infectious sequelae component, this warrants further studies on long term disease 
outcomes. Since we made use of expert panel facilitation, careful interpretation of post-infection sequelae 
proportions may be required. Fourth, so far, we have included only regional age/sex distribution and 
country specific life expectancy values for post-infectious sequelae, but have been unable to include any 
regional differences in disease presentation and sequelae, which may be linked to virulence,3 because of 
lack of data. Additionally, due to the lack of granularity we were unable to differentiate for transition 
between disease states and therefore we assumed to be similar across health-care systems globally.  Fifth, 
as yet, reactivation of latent melioidosis does not seem to play a major role in the total burden of 
melioidosis, however, crucial data on this subject are missing and we are currently unable to determine 
exact figures. Sixth, we did not account for trends of increasing or decreasing melioidosis incidence that 
could have occurred across countries, because of the limited amount of data available. We found that 
extracting data from regional/national databases would not be representative, as exemplified by data 
validation in Thailand (webappendix pp 4).32 Last, the nature of our study and modelling work only allowed 
us to generate estimates up to 2015. Extrapolation of estimates beyond this time point was considered, 
but this would have led to further widening of uncertainty intervals. Additionally, accurate populations 
estimates are only available up to 2015, hence reducing the ambiguity in modelling estimates of estimates. 
Moreover, in order to be consistent with the incidence and mortality rates for 2015 used, we only included 
data up to 2015 in our systematic review.4 Despite these limitations, we believe the systematic 
methodological approach we have taken has yielded more robust estimates than would otherwise have 
been obtained using limited source data of countrywide health statistics/vital registration forms.  
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Access to healthcare and socio-demographic development are associated with the burden of melioidosis 
as assessed by DALYs. Previously it has been shown that below a SDI score of 0.25, communicable causes 
accounted for 30-45% of total disability, with NTDs playing a primary role.33 Interestingly, the majority of 
melioidosis-endemic countries carry a higher SDI. This association between SDI and HAQ Index and DALYs 
allows one to benchmark those outliers showing a discrepant relationship for targeted improvement, at 
the same time providing insights into which public interventions contribute towards narrowing. Thus, 
efforts beyond reduction in income inequality, improved fertility or years of education (factors comprising 
SDI) will help catalyse additional gains in life expectancy and reduce disease burden (all-age YLDs), further 
emphasising the critical role of policy interventions beyond traditional health service delivery. For 
example, with increasing SDI, the proportion of workforce in agriculture would be expected to decrease, 
which is likely to have some effect on the burden of melioidosis as this group of population is at increased 
risk. It is important to note that the SDI instrument is still incomplete, because significant features of 
societal function are missing (including political stability, gender equity, urbanisation, technology 
penetration or infrastructure).34 As melioidosis is caused by a saprophytic organism, climate change will 
also impact geographic spread and incidence. Further aims include characterizing knowledge gaps in 
respective epidemiological disease parameters. One such aspect would be to characterise DALYs according 
to seasonal changes given the close relationship between melioidosis incidence, the monsoon and severe 
weather events, which will help further target interventions.  
 
Moreover, incidence data on melioidosis could vary depending on the surveillance system of the country 
(including whether it considers melioidosis a problem or not) and on the definition of case-based isolation 
of bacteria or detection by PCR or immunoassays test.30 Strengthening melioidosis notification and vital 
registration systems is needed to improve the quality of data.26 Until such systems are fully developed and 
integrated at national levels, it should be appreciated by users that variation in estimates is unavoidable. 
It is hoped from this work that endemic countries will be sensitised on the burden of the disease and the 
need to improve its surveillance in order to adapt control measures. Clearly, a key priority should be 
worldwide collaboration to fortify and develop basic microbiological diagnostic facilities (health 
technology) and capacity which forms the foundations of surveillance data, an area of importance also 
emphasised by the Lancet commission.35 This in itself would have wider implications for other 
diseases/pathogens, not least better clinical management of patients. 
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Efforts against NTDs reached a watershed after the first Global Partners’ Meeting convened by WHO in 
2007. This landmark initiative resulted in a shared commitment to support WHO’s strategies yielding 
significant gains for public health, including scale up of control and elimination programs and enhanced 
access to medicines. Subsequently, the first WHO report on NTDs demonstrated that the strategic 
approaches were technically feasible and the investment cost effective.36 We feel it is time that these gains 
are also translated across to melioidosis as our estimates provide a clear motivation for considering 
melioidosis as a major NTD. It meets the proposed criteria for classifying a condition as an NTD, in that it 
1) disproportionally affects populations living in poverty, causing important morbidity and mortality 2) 
primarily affects populations living in tropical and subtropical regions 3) is amenable to broad control, 
elimination or eradication strategies and 4) is relatively neglected by research funding allocation.37 Now 
that this precedent has been established, collaboration between member states and international 
partners, including organizations, foundations and donors is vital in order to increase international 
attention, prioritize national epidemiological surveillance, operational research and strengthen 
development of highly needed laboratory capacity, products and tools together with necessary public and 
health-care worker training. Due to the saprophytic nature of melioidosis and the fact that it can also affect 
a wide range of animal species, a One Health approach would be ideal.  
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Melioidosis disease states 
used in model 
Most similar sequela from GBD 
2015 
Description Disability Weight 
(95% CI) 
Septic shocka Intensive care unit admission 21 Intensive care unit admission used as surrogate for 
septic shock. 
0·655 
(0·579-0·727) 
Sepsisa Infectious disease: acute episode 
(severe) 
Has high fever and pain, and feels very weak, which 
causes great difficulty with daily activities. 
0·133 
(0·088-0·190) 
Pneumoniaa Infectious disease: acute episode 
(severe) is equivalent to lower 
respiratory infections (severe) 
Has high fever and pain, and feels very weak, which 
causes great difficulty with daily activities. 
0·133 
(0·088-0·190) 
Central nerve system 
infection (brain or spinal) 
Motor plus cognitive impairment 
(severe) 
Cannot move around without help, and cannot lift or 
hold objects, get dressed or sit upright. The person 
also has very low intelligence, speaks few words, and 
needs constant supervision and help with all daily 
activities. 
0·542 
(0·374-0·702) 
Intra-abdominal abscess 
(e.g. liver, spleen, pancreas) 
Abdominal/Pelvic problems 
(moderate) 
Has pain in the belly and feels nauseous. The person 
has difficulties with daily activities. 
0·114 
(0·078-0·159) 
Musculoskeletal infection 
(osteomyelitis or septic 
arthritis) 
Osteoarthritis (severe) Musculoskeletal problems, lower limb has severe pain 
in the leg, which makes the person limp and causes a 
lot of difficulty walking, standing, lifting and carrying 
heavy things, getting up and down, and sleeping. 
0·165 
(0·112-0·232) 
Urinary tract infection (e.g. 
prostatitis) 
Epididymo-orchitis Has swelling and tenderness in the testicles and pain 
during urination. 
0·128 
(0·086-0·180) 
Parotitis (+lymphadenitis) Infectious disease: acute episode 
(moderate) 
Has a fever and aches, and feels weak, which causes 
some difficulty with daily activities. 
0·051 
(0·032-0·074) 
Skin soft tissue infection Mild cellulitis Has a slight, visible physical deformity that is 
sometimes sore or itchy. Others notice the deformity, 
which causes some worry and discomfort. Has a low 
fever and mild discomfort, but no difficulty with daily 
activities. 
0·027 
(0·015-0·042) 
 
Other (mainly pericarditis 
and mycotic aneurysms) 
Infectious disease: acute episode 
(severe) 
Has high fever and pain, and feels very weak, which 
causes great difficulty with daily activities. 
0·133 
(0·088-0·190) 
Table 1: Disability weights used for the calculation of the disability-adjusted life years due to melioidosis 
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Most recent version of already established DWs of most similar sequelae were selected from the GBD 2015 update.20 For septic shock intensive 
care unit admission was used as a surrogate.21 When exact matches were not available, proxy disease outcomes were identified based on the best 
matching description and expert opinion. We considered all pneumonia cases to be severe, because a priori evidence shows that primary 
pneumonia due to B. pseudomallei is acute in the majority of patients (>90%) and frequently rapidly progresses to sepsis and death.22 
By definition, DWs range on a scale from 0 (perfect health) to 1 (death).  
a Septic shock, sepsis, pneumonia, only acute cases were included  
Abbreviations: CI = confidence interval, DW= disability weight and GBD= Global Burden Disease. 
 
 
 
 
Oral treatment Generic uncomplicated disease: 
worry and daily medication 
Has a chronic disease that requires medication every 
day and causes some worry but minimal interference 
with daily activities. 
0·049 (0·031-0·072) 
Post sepsis and septic shock 
sequelae 
Infectious disease: Post-acute 
effects (fatigue, emotional lability, 
and insomnia) 
Is always tired and easily upset. The person feels pain 
all over the body and is depressed. 
0·217 
(0·179 – 0·251) 
 
Ongoing neurologic 
impairment 
Infectious disease: Post-acute 
effects (fatigue, emotional lability, 
and insomnia) 
Is always tired and easily upset. The person feels pain 
all over the body and is depressed. 
0·217 
(0·179 – 0·251) 
Ongoing musculoskeletal 
problems 
Osteoarthritis (severe) Musculoskeletal problems, lower limb has severe pain 
in the leg, which makes the person limp and causes a 
lot of difficulty walking, standing, lifting and carrying 
heavy things, getting up and down, and sleeping. 
0·165 (0·112 – 
0·232) 
 
19 
 
Country YLL  
(95% UI) 
YLL per 
100·000   
(95% UI) 
YLD  
(95% UI)  
YLD per 100·000  
(95% UI) 
DALY  
(95% UI)  
DALY per 
100·000  
(95% UI) 
African Region 769 448 (394 742-1 399 395) 83 (43-152) 5 817 (2 240-12 735) 0·631 (0·243-1·4) 775 266 (400 236-1 405 485) 84 (43-152) 
Angola 984 (61-3 199) 3·5 (0·218-11) 8·8 (0·590-31) 0·032 (0·002-0·111) 993 (68-3 206) 3·6 (0·246-12) 
Benin 29 154 (6 264-69 760) 276 (59-660) 241 (44-671) 2·3 (0·419-6·3) 29 395 (6 510-69 975) 278 (62-662) 
Burkina Faso 20 685 (2 802-56 695) 114 (15-313) 165 (20-509) 0·911 (0·112-2·8) 20 850 (2 948-56 834) 115 (16-314) 
Cameroon 17 362 (2 608-46 249) 76 (11-203) 141 (20-420) 0·616 (0·087-1·8) 17 503 (2 738-46 378) 77 (12-203) 
Central African Republic 4 479 (792-11 460) 99 (17-252) 33 (5·2-95) 0·725 (0·115-2·1) 4 512 (825-11 489) 99 (18-253) 
Chad 13 457 (1 460-38 811) 96 (10-277) 103 (10-331) 0·738 (0·074-2·4) 13 561 (1 567-38 928) 97 (11-278) 
Congo 8 295 (1 854-19 696) 166 (37-394) 68 (13-186) 1·4 (0·264-3·7) 8 363 (1 921-19 769) 167 (38-396) 
Côte d'Ivoire 36 423 (7 354-89 402) 158 (32-387) 264 (44-756) 1·1 (0·192-3·3) 36 686 (7 599-89 665) 159 (33-388) 
DRC 7 214 (769-20 814) 9·5 (1·0-27) 61 (6·2-197) 0·080 (0·008-0·258) 7 275 (830-20 871) 9·5 (1·1-27) 
Equatorial Guinea 194 (39-477) 17 (3·3-41) 1·4 (0·251-4·0) 0·121 (0·021-0·342) 196 (41-478) 17 (3·4-41) 
Eritrea 845 (59-2 675) 17 (1·2-55) 8·5 (0·686-29) 0·174 (0·014-0·589) 854 (68-2 683) 18 (1·4-55) 
Ethiopia 8 399 (874-24 387) 8·4 (0·875-24) 76 (8·0-242) 0·076 (0·008-0·243) 8 475 (950-24 473) 8·5 (0·951-25) 
Gabon 1 410 (323-3 323) 73 (17-172) 12 (2·2-33) 0·619 (0·112-1·7) 1 422 (335-3 335) 74 (17-173) 
Gambia 255 (6·3-940) 13 (0·319-48) 2·8 (0·151-10) 0·140 (0·008-0·518) 257 (9·0-942) 13 (0·454-48) 
Ghana 13 096 (1 335-38 275) 47 (4·8-139) 107 (9·7-352) 0·389 (0·035-1·3) 13 203 (1 443-38 382) 48 (5·2-139) 
Guinea 42 961 (8 864-104 561) 355 (73-865) 333 (61-928) 2·8 (0·502-7·7) 43 294 (9 190-104 890) 358 (76-867) 
Guinea-Bissau 3 315 (375-9 442) 187 (21-533) 26 (2·8-82) 1·5 (0·161-4·6) 3 341 (402-9 472) 189 (23-535) 
Kenya 3 187 (413-8 852) 6·7 (0·875-19) 29 (3·5-90) 0·061 (0·007-0·190) 3 216 (442-8 879) 6·8 (0·935-19) 
Liberia 14 131 (2 751-35 137) 314 (61-781) 111 (19-317) 2·5 (0·414-7·0) 14 242 (2 868-35 269) 317 (64-784) 
Madagascar 27 359 (5 851-65 662) 113 (24-271) 235 (43-657) 0·972 (0·179-2·7) 27 594 (6 107-65 878) 114 (25-272) 
Malawi 6 894 (1 242-17 539) 39 (7·1-100) 57 (9·4-163) 0·325 (0·054-0·929) 6 951 (1 303-17 587) 40 (7·4-100) 
Mali 19 197 (2 763-51 629) 110 (16-296) 151 (20-459) 0·863 (0·112-2·6) 19 348 (2 913-51 768) 111 (17-296) 
Mauritania 958 (74-2 977) 23 (1·8-71) 8·0 (0·572-28) 0·192 (0·014-0·661) 966 (82-2 987) 23 (2·0-71) 
Mauritius 101 (9·1-302) 8·0 (0·720-24) 2·4 (0·212-8·0) 0·190 (0·017-0·633) 103 (11-304) 8·2 (0·887-24) 
Mozambique 7 613 (966-21 195) 27 (3·4-76) 62 (7·7-192) 0·223 (0·028-0·686) 7 675 (1 026-21 253) 27 (3·7-76) 
Niger 12 146 (1 034-36 906) 61 (5·2-185) 103 (8·5-349) 0·520 (0·043-1·8) 12 249 (1 130-37 026) 62 (5·7-186) 
Nigeria 426 571 (89 803-1 031 369) 235 (50-569) 3 070 (551-8 590) 1·7 (0·304-4·7) 429 641 (92 865-1 034 804) 237 (51-571) 
Senegal 2 097 (118-6 906) 14 (0·789-46) 18 (1·1-65) 0·123 (0·008-0·435) 2 115 (135-6 929) 14 (0·904-46) 
Sierra Leone 19 140 (3 758-47 287) 264 (52-653) 132 (23-375) 1·8 (0·321-5·2) 19 272 (3 884-47 455) 266 (54-656) 
Table 2 Melioidosis global disability-adjusted life years distribution with breakdown per country in 2015   
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South Africa 856 (64-2 678) 1·5 (0·116-4·8) 8·2 (0·696-27) 0·015 (0·001-0·049) 864 (72-2 686) 1·6 (0·130-4·9) 
South Sudan 1 189 (120-3 492) 10 (1·0-29) 11 (1·2-35) 0·092 (0·010-0·292) 1 200 (131-3 504) 10 (1·1-29) 
Tanzania 9 561 (1 272-26 347) 18 (2·4-49) 86 (11-264) 0·159 (0·019-0·490) 9 647 (1 354-26 437) 18 (2·5-49) 
Togo 5 030 (748-13 431) 68 (10-181) 39 (5·1-119) 0·531 (0·069-1·6) 5 070 (783-13 474) 68 (11-182) 
Uganda 1 026 (37-3 620) 2·6 (0·092-9·0) 9·7 (0·477-36) 0·024 (0·001-0·090) 1 036 (47-3 629) 2·6 (0·116-9·0) 
Zambia 3 635 (424-10 318) 23 (2·6-64) 31 (3·6-96) 0·191 (0·022-0·595) 3 666 (454-10 350) 23 (2·8-64) 
Zimbabwe 230 (15-733) 1·5 (0·098-4·6) 2·2 (0·158-7·4) 0·014 (<0·001-0·047) 232 (18-735) 1·5 (0·111-4·7) 
American Region 68 431 (36 003-118 711) 12 (6·3-21) 1 291 (460-2 892) 0·225 (0·080-0·504) 69 722 (37 135-120 070) 12 (6·5-21) 
Argentina 565 (37-1 801) 1·3 (0·085-4·1) 11 (0·652-41) 0·026 (0·002-0·093) 577 (47-1 815) 1·3 (0·108-4·2) 
Bolivia  573 (49-1 735) 5·3 (0·458-16) 5·8 (0·479-19) 0·054 (0·004-0·182) 579 (55-1 741) 5·4 (0·509-16) 
Brazil 26 116 (3 852-69 412) 13 (1·9-34) 517 (64-1 598) 0·251 (0·031-0·776) 26 632 (4 304-70 044) 13 (2·1-34) 
Colombia 4 808 (725-12 722) 10·0 (1·5-26) 88 (12-267) 0·182 (0·024-0·554) 4 896 (806-12 817) 10 (1·7-27) 
Costa Rica 391 (71-988) 8·1 (1·5-21) 11 (1·6-32) 0·225 (0·033-0·666) 402 (81-1 000) 8·4 (1·7-21) 
Cuba 426 (21-1 428) 3·7 (0·181-12) 17 (0·791-62) 0·146 (0·007-0·542) 442 (34-1 444) 3·9 (0·296-13) 
El Salvador 3 206 (769-7 411) 51 (12-117) 59 (12-160) 0·934 (0·184-2·5) 3 265 (827-7 470) 52 (13-118) 
Guatemala 2 454 (443-6 205) 15 (2·7-38) 31 (4·7-90) 0·189 (0·029-0·553) 2 485 (474-6 234) 15 (2·9-38) 
Guyana 449 (86-1 118) 58 (11-146) 4·7 (0·675-14) 0·606 (0·088-1·8) 453 (90-1 122) 59 (12-146) 
Haiti 1 129 (89-3 472) 11 (0·835-32) 8·9 (0·804-29) 0·083 (0·008-0·274) 1 138 (98-3 481) 11 (0·918-32) 
Honduras 2 894 (400-7 833) 32 (4·5-87) 45 (6·2-136) 0·503 (0·069-1·5) 2 939 (443-7 879) 33 (4·9-88) 
Mexico 16 128 (2 711-41 615) 13 (2·2-33) 328 (45-987) 0·260 (0·036-0·784) 16 456 (3 012-41 937) 13 (2·4-33) 
Nicaragua 2 205 (379-5 651) 36 (6·2-93) 33 (4·8-98) 0·546 (0·079-1·6) 2 238 (411-5 690) 37 (6·8-94) 
Panama 1 995 (465-4 657) 50 (12-117) 38 (7·3-104) 0·954 (0·184-2·6) 2 033 (500-4 694) 51 (13-118) 
Paraguay 455 (12-1 670) 6·9 (0·177-25) 8·6 (0·358-32) 0·129 (0·005-0·486) 464 (19-1 679) 7·0 (0·291-25) 
Peru 1 227 (155-3 389) 3·9 (0·493-11) 22 (2·7-69) 0·070 (0·008-0·219) 1 249 (175-3 411) 4·0 (0·558-11) 
Suriname 439 (94-1 052) 79 (17-190) 6·6 (1·1-19) 1·2 (0·200-3·4) 446 (100-1 059) 81 (18-191) 
Venezuela 2 970 (533-7 511) 9·5 (1·7-24) 58 (8·6-170) 0·185 (0·028-0·546) 3 028 (590-7 569) 9·7 (1·9-24) 
Eastern Mediterranean 
Region 
18 448 (6 357-42 250) 4·4 (1·5-10) 101 (31-252) 0·024 (0·007-0·060) 18 549 (6 460-42 347) 4·4 (1·5-10) 
Iran  279 (9·5-981) 0·351 (0·012-
1·2) 
3·0 (0·106-11) 0·004 (<0·001-0·014) 282 (12-983) 0·355 (0·016-
1·2) 
Iraq 562 (9·1-2 200) 1·6 (0·025-6·1) 3·4 (0·052-14) 0·010 (<0·001-0·040) 566 (12-2 204) 1·6 (0·034-6·1) 
Oman 84 (20-194) 2·0 (0·468-4·6) 1·1 (0·162-3·2) 0·026 (0·004-0·077) 85 (21-195) 2·0 (0·493-4·7) 
Pakistan 11 193 (848-34 627) 5·9 (0·448-18) 57 (4·3-190) 0·030 (0·002-0·100) 11 250 (900-34 705) 5·9 (0·475-18) 
Saudi Arabia 675 (65-1 992) 2·1 (0·205-6·3) 10·0 (0·858-33) 0·032 (0·003-0·104) 685 (73-2 002) 2·2 (0·233-6·3) 
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Somalia 1 776 (166-5 271) 13 (1·2-38) 7·8 (0·726-25) 0·056 (0·005-0·181) 1 783 (174-5 280) 13 (1·3-38) 
Sudan 1 555 (95-5 014) 4·0 (0·245-13) 7·9 (0·515-27) 0·020 (0·001-0·070) 1 563 (102-5 023) 4·0 (0·265-13) 
Yemen 2 324 (398-5 934) 8·6 (1·5-22) 11 (1·6-31) 0·040 (0·006-0·115) 2 334 (408-5 945) 8·7 (1·5-22) 
South-east Asian Region 2 974 407 (1 649 716-4 835 
486) 
156 (87-254) 30 640 (12 500-62 
865) 
1·6 (0·658-3·3) 3 005 047 (1 678 472-4 866 
872) 
158 (88-256) 
Bangladesh 471 829 (162 015-944 388) 293 (101-586) 4 974 (1 366-11 993) 3·1 (0·848-7·4) 476 803 (166 451-949 640) 296 (103-589) 
Bhutan 433 (87-1 052) 55 (11-134) 3·8 (0·552-11) 0·487 (0·070-1·4) 437 (91-1 055) 55 (12-134) 
India 1 583 214 (490 572-3 306 747) 121 (37-253) 13 518 (3 390-33 
836) 
1·0 (0·259-2·6) 1 596 733 (503 727-3 320 277) 122 (38-254) 
Indonesia 532 334 (132 919-1 210 328) 206 (51-469) 6 147 (1 297-16 220) 2·4 (0·503-6·3) 538 480 (138 880-1 216 825) 209 (54-471) 
Myanmar 187 137 (52 103-407 584) 357 (99-778) 1 596 (372-4 086) 3·0 (0·710-7·8) 188 733 (53 729-409 251) 360 (103-781) 
Nepal 25 799 (6 147-59 555) 90 (21-208) 259 (54-690) 0·903 (0·189-2·4) 26 057 (6 394-59 808) 91 (22-209) 
Sri Lanka 30 677 (8 849-65 909) 148 (43-318) 834 (196-2 159) 4·0 (0·946-10) 31 511 (9 655-66 771) 152 (47-322) 
Thailand 142 641 (46 506-291 800) 208 (68-425) 3 305 (848-8 261) 4·8 (1·2-12) 145 946 (49 726-295 285) 213 (72-430) 
Timor-Leste 343 (40-964) 28 (3·2-78) 2·8 (0·307-8·7) 0·225 (0·025-0·703) 346 (43-967) 28 (3·5-78) 
West-Pacific Region 754 360 (454 818-1 157 728) 45 (27-69) 12 693 (5 185-26 
073) 
0·754 (0·308-1·5) 767 053 (466 874-1 170 486) 46 (28-70) 
Australia 1 963 (450-4 584) 8·2 (1·9-19) 99 (19-276) 0·417 (0·078-1·2) 2 062 (536-4 697) 8·7 (2·3-20) 
Brunei Darussalam 481 (159-981) 115 (38-235) 15 (3·5-38) 3·6 (0·835-9·2) 496 (173-995) 119 (41-238) 
Cambodia 63 674 (16 627-142 051) 410 (107-915) 654 (141-1 723) 4·2 (0·909-11) 64 328 (17 359-142 676) 415 (112-919) 
China 136 733 (47 558-272 254) 9·8 (3·4-19) 3 226 (880-7 859) 0·231 (0·063-0·563) 139 958 (50 709-275 425) 10 (3·6-20) 
Fiji 103 (13-283) 12 (1·5-32) 1·6 (0·163-5·1) 0·180 (0·018-0·574) 105 (15-285) 12 (1·7-32) 
Laos 14 058 (3 998-30 345) 211 (60-455) 112 (25-291) 1·7 (0·382-4·4) 14 170 (4 110-30 455) 213 (62-457) 
Malaysia 28 564 (7 665-63 033) 93 (25-205) 912 (195-2 431) 3·0 (0·635-7·9) 29 476 (8 435-64 088) 96 (27-209) 
Papua New Guinea 4 311 (997-10 032) 54 (13-127) 33 (6·7-89) 0·421 (0·084-1·1) 4 344 (1 031-10 064) 55 (13-127) 
Philippines 240 606 (95 218-453 084) 237 (94-445) 2 976 (934-6 893) 2·9 (0·918-6·8) 243 582 (98 035-456 063) 239 (96-448) 
Singapore 2 808 (284-8 173) 51 (5·1-148) 202 (22-633) 3·6 (0·406-11) 3 010 (456-8 379) 54 (8·2-151) 
Vietnam 261 059 (65 691-591 358) 279 (70-632) 4 462 (940-11 849) 4·8 (1·0-13) 265 521 (70 102-596 432) 284 (75-637) 
GLOBAL 4 585 094 (3 114 498-6 550 
593) 
83 (57-119) 50 542 (22 778-97 
825) 
0·919 (0·414-1·8) 4 635 636 (3 164 157-6 602 
075) 
84 (58-120) 
 
DALYs are presented per country in associated region from highest to lowest DALY. Abbreviations: DRC= Democratic Republic of Congo; 
UI=uncertainty interval; YLL= years life lost; YLD= years lived with disability and DALY= disability-adjusted life years. 
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FIGURE LEGENDS 
 
Figure 1: Simplified disease model used to estimate the global burden of melioidosis  
All surviving patients were considered to receive oral antibiotic treatment. Sequelae data on post-acute 
melioidosis consequences were also extracted from additional literature searches for sepsis and septic 
shock,16 ongoing neurologic impairment,17 and ongoing MSK problems.18,19 Abbreviations: CNS= central 
nervous system; MSK= musculoskeletal; UTI= urinary tract infection; SSTI= skin soft tissue infection. 
 
Figure 2: Age and sex distribution of melioidosis incident and fatal cases  
 
Figure 3: Disability-adjusted life years per 100 000 people for melioidosis by country in 2015 
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Appendix A: Methods 
 
A.1: Databases and Boolean operators (last search on 08 August 2018)  
 
Table S1: Databases and Boolean operators (last search on 08 August 2018). 
 
Databases Melioidosis classification terms Results 
Medline 1: (Melioidosis or Burkholderia pseudomallei or Pseudomonas 
pseudomallei or Bacillus pseudomallei or Bacterium whitmori or 
"Whitmore* disease").ti,ab,kf. 
2: exp Melioidosis/ 
3. exp Burkholderia pseudomallei 
4: 1 or 2 or 3 
5: limit 4 to yr=”1990-2015” 
2394 
 
 
Embase 1: exp melioidosis/ 
2: Burkholderia pseudomallei/ 
3: (Melioidosis or Burkholderia pseudomallei or Pseudomonas 
pseudomallei or Bacillus pseudomallei or Bacterium whitmori or 
"Whitmore* disease").ti,ab,kw. 
4: 1 or 2 or 3 or 4 
5: limit 4 to (conference abstract or conference paper or "conference 
review") 
6: "review"/ 
7: 5 or 6 
8: 4 not 7 
9 limit 8 to Embase 
10: limit 9 to yr=”1990-2015” 
2067 
WHO Global health librarya tw:(tw:((melioidosis OR "Burkholderia pseudomallei" OR 
"Pseudomonas pseudomallei" OR "Bacillus pseudomallei" OR 
"Bacterium whitmori" OR "Whitmore* disease")) AND (instance:"ghl") 
AND ( db:("IMSEAR" OR "WPRIM" OR "LILACS" OR "WHOLIS" 
OR "IMEMR")) ) AND (instance:"ghl") AND ( year_cluster:("2009" 
OR "2011" OR "2012" OR "2015" OR "2005" OR "2013" OR "1991" 
OR "2006" OR "2008" OR "1996" OR "1997" OR "2007" OR "2001" 
OR "2004" OR "2010" OR "2003" OR "1995" OR "2000" OR "1993" 
OR "1998" OR "1992" OR "1994" OR "1999" OR "2002" OR "2014" 
OR "1990")) 
257 
Melioidosis.infob http://www.melioidosis.info/info.aspx?pageID=107 
No <1990 or > 2015 
352 
 
a The WHO Global Health library includes regional and other indexes such as AIM (AFRO), LILACS (AMRO/PAHO), 
IMEMR (EMRO), IMSEAR (SEARO), WPRIM (WPRO), MEDLINE, SciELO and WHO IRIS. 
b Researchers, clinicians and public health officials can report all melioidosis cases on this website run by the 
Melioidosis Research Coordination Network.  
 
Due to paucity of data available for post-infectious sequelae, particularly those related to melioidosis; we conducted a 
search with expert opinion facilitation and made use of large observational or systematic reviews regarding the specific 
post-infectious outcomes. 
 
 
  
4 
 
We identified national surveillance systems for example that in Thailand. This highly researched and melioidosis-
endemic country sees more than 2000 culture-confirmed cases of melioidosis each year with a mortality rate of 
approximately 35%. Previously, only about 10 melioidosis deaths were formally reported to the National Notifiable 
Disease surveillance system (Report 506) each year. In 2015, the number of formally reported melioidosis deaths rose 
to 112 solely because Sunpasithiprasong Hospital, Ubon Ratchathani province, reported its own data (n=107) for the 
first time.2 The discrepancy between the true numbers of melioidosis cases and deaths and those that are reported 
shows that it is likely the current national surveillance reports reflect only the tip of the iceberg. The fact that 
melioidosis is not officially listed as a reportable disease in most endemic countries shows that extracting data from 
regional/national databases is not yet the way to get an accurate picture of the burden of melioidosis. 
 
Furthermore, we looked previously at the Eurosurveillance database (last search March 2017) and found 39 cases of 
melioidosis. Most of these were listed as ‘probable’ or ‘suspected’ melioidosis cases and the quality of the 
microbiological and clinical data was very limited. Additionally, a paper published in 2015 reviewed the literature on 
melioidosis in travellers and included 72 cases of which 50 were from Europe.3 The number of cases in the 
Eurosurveillance database is thus lower than the number of cases reported in the literature. The cases in the literature 
are much better described and we have included those papers in our systematic review. Consequently, we decided not 
to include the Eurosurveillance database. 
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A.2: Inclusion, exclusion criteria 
 
Inclusion criteria  
Criteria for articles to be considered for TIAB inclusion: 
- Human, culture positive Burkholderia pseudomallei 
 
Criteria for inclusion based on full text analysis: 
- Human, culture positive B. pseudomallei 
 
Exclusion criteria: 
- Article does not pertain B. pseudomallei or melioidosis e.g. 
- Article pertains solely to prevalence of B. pseudomallei in animals  
- Article pertains solely to prevalence of B. pseudomallei in environment 
- Article pertains solely laboratory methods for melioidosis diagnosis 
- Article pertains solely the characterization of B. pseudomallei strains 
- Article pertains solely diagnosis with serology 
- Article pertains solely in to immunology or pathogenesis of melioidosis 
- Article pertains solely to melioidosis as vaccine carrier 
- Article published before 1990 or after 2015 
- Diagnosis of the cases <1990 or after 2015 
- Article without abstract, unclear abstract 
- Article duplicated 
- Article referred to a larger study 
- Article not available  
- Article not translatable 
 
Cases occurring before 1990, after 2015, or diagnosed by serology were excluded from the analysis, unless included 
within culture-positive summary statistics. If only publication year was available or we were unable to separate out 
data overlapping with excluded time periods, we assumed it to meet our inclusion criteria. 
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A.3: Flow diagram 
 
Figure S1: PRISMA flow diagram of study selection  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
References containing quantitative datasets for the estimation of the global burden of melioidosis are referenced in 
the link in webappendix pp 35.  
 
Abbreviations: CNS= central nervous system; Abscess IA= Abscess intra-abdominal; MSK= musculoskeletal; UTI= 
urinary tract infection; SSTI= skin soft tissue infection. 
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A.4: Data extracted from melioidosis database 
 
Author - Date of publication - Journal - Title - PMID - Population size in year of data collection – Country of origin – 
Country infected– WHO region - Study area – Study design - Timeframe of the study - Study population - Case 
definition - Number of cases of melioidosis (overall) - Number of cases of melioidosis by age group - Number of cases 
by year - Mean number of cases by year - Proportion of cases by age group (%) - Mean [Median] age of cases (in 
years) - Standard deviation of mean [Range] (in years) - Number of septicemia caused by melioidosis – Proportion of 
septicemia caused by melioidosis (%) - Duration of symptoms prior admission septicemia (in days) - Duration of  
hospitalization septicemia (in days) - Number of septic shock caused by melioidosis- Proportion of septic shock caused 
by melioidosis (%) - Duration of symptoms prior admission septic shock (in days) - Duration of  hospitalization septic 
shock (in days) - Number of pneumonia caused by melioidosis - Proportion of pneumonia (%) - Duration of symptoms 
prior admission pneumonia (in days) - Duration of hospitalization pneumonia (in days) - Number of central nervous 
system infections caused by melioidosis (CNS) - Proportion of CNS (%) - Duration of symptoms prior admission CNS 
(in days) - Duration of  hospitalization CNS (in days) - Number of intra-abdominal abscesses caused by melioidosis - 
Proportion of intra-abdominal abscesses (%) - Duration of symptoms prior admission intra-abdominal abscesses (in 
days) - Duration of  hospitalization intra-abdominal abscesses (in days) - Number of parotitis/lymphadenitis caused by 
melioidosis - Proportion parotitis/lymphadenitis (%) - Duration of symptoms prior admission parotitis/lymphadenitis 
(in days) - Duration of  hospitalization parotitis/lymphadenitis (in days) - Number of urinary tract infection (UTI) 
caused by melioidosis - Proportion UTI (%) - Duration of symptoms prior admission UTI (in days) - Duration of  
hospitalization UTI (in days) - Number of skin soft tissue infection (SSTI) caused by melioidosis - Proportion SSTI 
(%) - Duration of symptoms prior admission SSTI (in days) - Duration of hospitalization SSTI (in days) - Number of 
other outcome - Proportion other outcome (%) - Duration of symptoms prior admission other outcome (in days) - 
Duration of hospitalization other outcome (in days) - Number of acute cases caused by melioidosis - Proportion of 
acute cases caused by melioidosis - Number of chronic cases caused by melioidosis – Proportion of chronic cases 
caused by melioidosis - Number of death - Duration of oral treatment (in days) - Number of Comorbidities (diabetes 
mellitus, liver cirrhosis, chronic kidney disease, chronic lung disease) - Proportion of comorbidities (diabetes mellitus, 
liver cirrhosis, chronic kidney disease, chronic lung disease) (%) - Comorbidities (diabetes mellitus, liver cirrhosis, 
chronic kidney disease, chronic lung disease) per disease outcome. 
 
Abbreviations: PMID= PubMed identification number; WHO= World Health Organization and ICU= intense care unit. 
 
The melioidosis DALY database contained a total of 11 767 patients across 5 WHO regions and 47 countries. 
Quantitative data was extracted by three authors, EB, HV and JS. EB and HV subsequently validated the database, 
removing duplication of data in published literature and ensured quality data extraction by cross-check validation of 
the whole database and subsequent random re-sampling. Additionally, some fields were standardized in that all patients 
on ICU were considered at least septic, all septic shock patients were also classified as septic and duration of 
intravenous antibiotics was used as a surrogate for hospitalization days. The term lymphadenitis mainly refers to head 
and neck region (i.e. cervical), however, cases of isolated lymphadenitis elsewhere (e.g. inguinal) were also included 
within this category. Other outcomes consisted of pericarditis and mycotic aneurysms predominantly.  
 
  
8 
 
We assumed that studies captured all culture-confirmed cases. We do not know enough about latent infection with B. 
pseudomallei or asymptomatic disease, although it certainly does exist.4 Additionally, whilst milder disease might be 
detected by antigen (or possibly antibody) testing, we used culture confirmation in order to be more robust. So there 
are certainly cases that may have been excluded and which may have been of varying severity. See also our fifth 
limitation in the discussion. 
For incidence rates, the modelling work aimed to estimate the incidence rates of culture-confirmed melioidosis cases. 
The work assumed that if incidence rates of culture-confirmed melioidosis (per 100,000 population/year) reported in 
or estimated from epidemiological studies with data for incidence rates (Limmathurotsakul et al., supplementary figure 
6) represent incidence rates of culture-confirmed melioidosis in each area, incidence rates of culture-confirmed 
melioidosis among people living in the other areas could be estimated based on the B. pseudomallei suitability and the 
prevalence of diabetes and aboriginal population.5 
 
The model did not include symptomatic cases who did not have access to healthcare in epidemiological studies with 
data for incidence rates (Limmathurotsakul et al, supplementary figure 6) and who had no culture positivity for B. 
pseudomallei.5 
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A.5: PRISMA guidelines 
Table S2: PRISMA Checklist for the Systematic Review and Meta-analysis to Estimate the Global Burden of Melioidosis circa 2015..1 
 
 
Section/topic  
 
 
# Checklist item  
Reported on 
page #  
TITLE  
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT 
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; 
study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.  
2 
INTRODUCTION 
Rationale  3 Describe the rationale for the review in the context of what is already known.  3-4 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design 
(PICOS).  
4-5 
METHODS 
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including 
registration number.  
6 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as 
criteria for eligibility, giving rationale.  
6-8 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date 
last searched.  
SA 3-4 & Figure 
S1 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.  SA 3-4 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).  6 & SA 5 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data 
from investigators.  
6-8 & SA 7-8 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.  SA 3-5 
Risk of bias in individual studies  12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), 
and how this information is to be used in any data synthesis.  
6-8 & SA 16-21 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  6-8 & SA 18 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.  SA 16-21 
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).  6-8, 11 & SA 16-
21 
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Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.  7-8 
RESULTS 
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow 
diagram.  
Figure S1 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.  Figure S1 & SA 6, 
34 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  NA 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and 
confidence intervals, ideally with a forest plot.  
NA 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  9-10 & SA 22-33 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  SA 22-33 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  9-10 
DISCUSSION 
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare 
providers, users, and policy makers).  
11-12 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).  12-14 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  11 & 15 
FUNDING 
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.  2 
 11 
 
A.6: Statement of GATHER compliance  
 
Table S3: GATHER checklist of information that should be included in reports of global health estimates, with description of compliance and location of information6  
 
 
Item # GATHER Checklist item Description of compliance  Reported on page# 
Objectives and funding  
1 Define the indicator(s), populations (including age, sex, and geographic entities), and time 
period(s) for which estimates were made. 
Narrative provided in paper describing  
indicators, definitions, time periods, and  
populations.  
Main text (Introduction, Methods) 
 
2 List the funding sources for the work. Funding sources listed in paper. Main text (Summary, Funding) 
Data Inputs  
   For all data inputs from multiple sources that are synthesized as part of the study:  
3 Describe how the data were identified and how the data were accessed.  All data seeking methodology referenced in main text.  Main text (Methods) 
 
4 Specify the inclusion and exclusion criteria. Identify all ad-hoc exclusions. All inclusion and exclusion criteria by data type referenced i
n main text and in appendix. 
 
Main text (Methods) & SA pp 5 
5 Provide information on all included data sources and their main characteristics. For each data 
source used, report reference information or contact name/institution, population represented, 
data collection method, year(s) of data collection, sex and age range, diagnostic criteria or 
measurement method, and sample size, as relevant.  
Online data platform that provides references to studies 
included.  
 
1. References of included studies are attached as 
necessary additional data 
(Will be live with publication on refworks.com)  
SA pp 36 
6 Identify and describe any categories of input data that have potentially important biases (e.g., 
based on characteristics listed in item 5). 
Post infectious sequelae were based on few publications, 
each with a small sample size. We addressed this in our 
uncertainty analysis, i.e., larger uncertainty because the 
smaller sample size. There are some methodological 
uncertainties, i.e. the DWs that had to be mapped to GBD 
health states because not all melioidosis health states have 
DWs; and the standard LE table, for which we used 2 
versions (and thus addressed the uncertainty). 
Main text (Methods) & SA 16-21 
 
   For data inputs that contribute to the analysis but were not synthesized as part of the study:  
7 Describe and give sources for any other data inputs.  All additional data inputs are included. Main text and references 
   For all data inputs:  
 12 
 
8 Provide all data inputs in a file format from which data can be efficiently extracted (e.g., a 
spreadsheet rather than a PDF), including all relevant meta-data listed in item 5. For any data 
inputs that cannot be shared because of ethical or legal reasons, such as third-party ownership, 
provide a contact name or the name of the institution that retains the right to the data. 
Downloads of input data will be available 
through refworks.com. 
Input data not available in tools will be made available 
upon request.   
 
1. References of included studies are attached as 
necessary additional data 
(Will be live with publication on refworks.com)  
SA pp 36 
Data analysis  
9 Provide a conceptual overview of the data analysis method. A diagram may be helpful.  Flow diagrams of the overall methodological have 
been provided. 
Main text (Methods) & SA pp 13 
10 Provide a detailed description of all steps of the analysis, including mathematical formulae. 
This description should cover, as relevant, data cleaning, data pre-processing, data adjustments 
and weighting of data sources, and mathematical or statistical model(s).  
Methodological write‐up for the calculation  
of DALYs have been provided.  
 
Main text (Methods) & SA 18 
 
11 Describe how candidate models were evaluated and how the final model(s) were selected. Provided in the methodological write‐up. Main text (Methods) & SA 
 
12 Provide the results of an evaluation of model performance, if done, as well as the results of any 
relevant sensitivity analysis. 
Provided in the methodological write‐ups and 
within appendix material.  
Main text & SA pp 1-27  
13 Describe methods for calculating uncertainty of the estimates. State which sources of 
uncertainty were, and were not, accounted for in the uncertainty analysis. 
Provided in the methodological write‐ups and 
within appendix material.  
 
Main text (Methods) & SA pp 16-21  
14 State how analytic or statistical source code used to generate estimates can be accessed. Access statement provided.  Git hub link for final submission, 
https://github.com/brechtdv/melioidosis 
Results and Discussion  
15 Provide published estimates in a file format from which data can be efficiently extracted. Estimates are provided in tables and will be made available 
on https://github.com/brechtdv/melioidosis 
Main text (Results, tables) & SA pp 22-33  
16 Report a quantitative measure of the uncertainty of the estimates (e.g. uncertainty intervals). Uncertainty intervals are provided with all  
results.  
 Main text (Results, tables) & SA 22-33 
17 Interpret results in light of existing evidence. If updating a previous set of estimates, describe 
the reasons for changes in estimates. 
Results are interpreted in light of existing evidence. Main text (Discussion)  
18 Discuss limitations of the estimates. Include a discussion of any modelling assumptions or data 
limitations that affect interpretation of the estimates. 
Discussion of limitations provided in the  
narrative of the main paper.  
Main text (Methods, Limitations) 
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A.7 Model flowchart  
 
Figure S2: Melioidosis DALY estimation flowchart. *Most recent version of already established DWs of most 
similar sequelae were selected from the GBD 2015 update.7 For septic shock intensive care unit admission was used 
as a surrogate.8 **Predicted incidence and mortality of melioidosis was derived from literature.9  
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A.8 WHO regions included  
Five of six World Health Organizations (WHO) regions are included. 
AFR= African Region 
Angola, Benin, Burkina Faso, Cameroon, Central African Republic, Chad, Congo, Côte d'Ivoire, Democratic Republic 
of the Congo, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Liberia, 
Madagascar, Malawi, Mali, Mauritania, Mauritius, Mozambique, Niger, Nigeria, Senegal, Sierra Leone, South Africa, 
South Sudan, Tanzania, Togo, Uganda, Zambia, Zimbabwe. 
 
AMR = Region of the Americas 
Argentina, Bolivia, Brazil, Colombia, Costa Rica, Cuba, El Salvador, Guatemala, Guyana, Haiti, Honduras, Mexico, 
Nicaragua, Panama, Paraguay, Peru, Suriname, Venezuela 
 
EMR = Eastern Mediterranean Region 
Iran, Iraq, Oman, Pakistan, Saudi Arabia, Somalia, Sudan, Yemen.  
 
SEAR = South-East Asia Region 
Bangladesh, Bhutan, India, Indonesia, Myanmar, Nepal, Sri Lanka, Thailand, Timor-Leste. 
 
WPR =Western Pacific Region 
Australia, Brunei Darussalam, Cambodia, China, Fiji, Laos, Malaysia, Papua New Guinea, Philippines, Singapore, 
Vietnam 
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A.9 SDI and HAQ index 
 
SDI is a composite indicator based on income, education, and fertility and was used as a summary measure of a 
geography’s socio-demographic development.10 It contains a scale from 0; lowest income per capita, lowest 
educational attainment and highest fertility, and 1 represents the highest income per capita, highest educational 
attainment and lowest fertility.10  
 
HAQ index is a score developed by the GBD which can be used as a robust method for tracking universal health 
access.11 This is a score between 0 to 100, estimated by a principle component analysis of three indicators from the 
GBD 2015 study (healthcare expenditure per capita, hospital beds per 1000, and the UHC tracer intervention index), 
a composite measure of 11 UHC tracer interventions (four childhood vaccinations, skilled birth attendance, coverage 
of at least one and four antenatal care visits, met need for family planning with modern contraception, tuberculosis 
case detection rates, insecticide-treated net coverage, and antiretroviral coverage for populations living with HIV); 
and three indicators from WHO (physicians, nurses, and midwives per 1000), the international Labour Organisation, 
and the World Bank (coverage index based on diphtheria-pertussis-tetanus vaccine coverage, coverage of at least four 
antenatal care visits, and proportion of children with diarrhoea receiving appropriate treatment).11 
 
Abbreviations: SDI=Socio-demographic Index; HAQ= Healthcare Access and Quality, GBD= Global Burden Disease 
and WHO= World Health Organization 
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A.10 Handling of missing data 
 
Systematic review and data synthesis 
Supplementary Figure S3 shows the association between missing country level data (from systematic review) and 
reported DALYs. The systematic review results were aggregated at global or regional level. The association in Figure 
S3 (taking into account non-zero study counts only), is positive, but rather weak. There is a cluster of high-burden, 
zero-studies countries in the top left part of the graph – all of them are AFR countries. There is a cluster of low-burden, 
many-studies countries in the mid bottom part of the graph – all of them are AMR countries. The SEAR and WPR 
countries appeared to have consistent DALY-to-studies ratios (high DALY, high study count), and likewise for the 
EMR countries (low DALY, low study count). 
 
 
Figure S3: Missing country level data and reported DALYs 
 
 
 
 
Abbreviations: SEAR=South-east Asian Region; AFR=African Region; AMR=American Region; EMR Eastern 
Mediterranean Region; WPR=West-Pacific Region 
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Incidence and mortality  
Additionally, previously published modelling work (Limmathurotsakul et al.) used a negative binomial model to 
estimate the incidence of melioidosis cases (per 100,000 population) based on the B. pseudomallei suitability and the 
prevalence of risk factors such as diabetes and aboriginal population. The B. pseudomallei suitability at a resolution 
of 5 km × 5 km was estimated using a boosted regression tree (BRT) statistical model and a database of occurrence 
records and a set of gridded environmental covariates known, or hypothesised, to affect the presence of B. 
pseudomallei. The occurrence records of melioidosis were based on 22,338 geo-located records from reports published 
from 1910 to 2014. For all countries, including countries with little published data on melioidosis, the strength of 
evidence for melioidosis endemicity at a national level, ranging from complete consensus on absence to complete 
consensus on presence, was defined. The strength of evidence was used in the formal modelling framework of the 
boosted regression tree statistical model as previously described and used for many other diseases. 
 
For incidence rates, the modelling work aimed to estimate the incidence rates of culture-confirmed melioidosis cases. 
The work assumed that if incidence rates of culture-confirmed melioidosis (per 100,000 population/year) reported in 
or estimated from epidemiological studies with data for incidence rates (Limmaturotsakul et al., supplementary figure 
6) represent incidence rates of culture-confirmed melioidosis in each area, incidence rates of culture-confirmed 
melioidosis among people living in the other areas could be estimated based on the B. pseudomallei suitability and 
the prevalence of diabetes and aboriginal population.5  
 
For mortality, the modelling work aimed to estimate the outcomes of culture-confirmed melioidosis cases. The work 
assumed that if case fatality rates of culture-confirmed melioidosis reported in epidemiological studies with data for 
case fatality rate (CFR) (Limmaturotsakul et al., supplementary figure 6) represent CFR of culture-confirmed 
melioidosis in those countries, CFR of culture-confirmed melioidosis in the other countries could be estimated based 
on the log10 transformed national-level under-5 mortality rate (U5MR) of that country.5 
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A.11 Uncertainty analysis 
 
Parameter uncertainty was quantified and propagated using 10,000 Monte Carlo simulations. The resulting uncertainty 
distributions were summarised by their mean and a 95% uncertainty interval (UI) defined as the distribution’s 2·5th 
and 97·5th percentile. 
 
Uncertainty in the country-specific incidence and mortality estimates9 was represented by Gamma distributions fitted 
using one-dimensional optimization to the estimated medians and 95% confidence intervals. Uncertainty in durations 
was represented by Gamma distributions fitted using the method of moments to the mean and standard deviation 
derived from the systematic review’s case data. Uncertainty in the probabilities of developing specific symptoms or 
post-infectious sequelae was represented by Beta distributions defined by numerators and denominators derived from 
the systematic review’s case data. Uncertainty in disability weights was represented by Beta distributions fitted using 
one-dimensional optimization to the disability weights’ means and 95% confidence intervals. 
 
The age and sex distribution of incident cases and deaths by WHO region was derived by pooling the cases from our 
systematic review. When individual data were not available, we simulated the age and sex distribution of the cases 
based on the available data. For the redistribution of age, we used PERT distributions if a minimum, maximum and 
point estimate were available; and uniform distributions if only a minimum and maximum age were available. If only 
a point estimate was available, the age was assigned to each case. For sex, a binomial distribution was used to divide 
patients per study into males/females according to the percentage of males. This approach was performed separately 
for all cases and for deaths, and results were pooled per WHO region. 
 
The uncertainty interval for our overall DALY estimate approximately spans +/- 50% the point estimate, which is 
quite wide but not uncommon for global burden estimates. As the DALY estimates were mainly driven by the years 
of life lost (YLL), the overall uncertainty was mainly a result of the uncertainty in the YLL estimates. For YLLs, we 
combined available mortality estimates by country with regional age distributions obtained through our systematic 
review. 
The relative uncertainty in these elements was lower than in the elements defining the years lived with disability 
(YLD), hence the overall low uncertainty. 
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A.12 Incidence and Mortality age distribution 
 
Figure S4. Regional age distribution for incidence (A) and mortality (B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: SEAR=South-east Asian Region; AFR=African Region; AMR=American Region; EMR Eastern 
Mediterranean Region; WPR=West-Pacific Region 
 
 
 
 
A 
B 
 20 
 
Figure S5 Data points regional age distribution for incidence (A) and mortality (B) 
 
 
 
A 
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B 
 
 
 
 
Abbreviations: SEAR=South-east Asian Region; AFR=African Region; AMR=American Region; EMR Eastern 
Mediterranean Region; WPR=West-Pacific Region 
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Melioidosis disease states used in 
model 
Overall Proportion Average duration of 
symptoms prior to 
admission (sd) 
Average duration of 
hospitalization (sd) 
Septic shock  1004/8298   
12·10% 
(UI 11·4-12·8) 
8·20 
(8·43) 
14·45 
(15·75) 
Sepsis 1526/8469  
18·02%  
(UI 17·2-18·8) 
9·26 
(8·84) 
18·86 
(15·80) 
Pneumonia 3633/10175 
35·71%  
(UI 34·8-36·6) 
10·85 
(10·61) 
21·42 
(17·26) 
Central nervous infection (brain or 
spinal) 
158/9827  
1·61% 
(UI 1·4-1·9) 
19·21 
(27·64) 
38·8 
(66·44) 
Abscess intra-abdominal 
(e.g. liver, spleen, pancreas) 
1619/8830  
18·32% 
(UI 17·5-19·1) 
67·35 
(206·37) 
32·93 
(60·18) 
Musculoskeletal infection 
(osteomyelitis or septic arthritis) 
805/9833  
8·19% 
(UI 7.7-8.7) 
63·30 
(168·81) 
 
33·92 
(56·15) 
 
Urinary tract infection (e·g. 
prostatitis) 
654/9833 
6·65% 
(UI 6·2-7·2) 
29·64 
(40·87) 
24·07 
(18·83) 
Parotitis (+lymphadenitis) 225/9833  
2·29% 
(UI 2·0-2·6) 
43·59 
(61·33) 
18·57 
(16·09) 
Skin soft tissue infection 1240/9833  
12·61% 
(UI 12·0-13·3) 
51·04 
(117·47) 
17.64 
(12·88) 
Other (mainly pericarditis and 
mycotic aneurysms) 
256/9832  
2·60% 
(UI 2·3-2·9) 
26·97 
(36·84) 
24·82 
(16·02) 
Post-sepsis and septic shock  1/612 
16·67% 
(UI 0·5-52·1) 
Post-infectious sequelae durations were modelled on the 
remaining life expectancy. 
 
Ongoing neurologic impairment 21/5813 
36·20% 
(UI 24·4-48·8) 
Ongoing musculoskeletal 
impairment  
83/20414,15  
40·69% 
(UI 34·1-47·5) 
 
All proportions, symptom duration prior admission and hospitalization numbers were calculated with the melioidosis 
DALY database, except post sepsis and septic shock,12 ongoing neurologic impairment,13 and ongoing 
musculoskeletal impairment 14,15 which were calculated with additional literature searches. Since melioidosis is mostly 
prevalent in LMIC, we made the assumption that intravenous antibiotic therapy was solely administered in-hospital 
and where hospital duration was missing intravenous antibiotic therapy duration could be used as a surrogate minimum 
time period.  
 
Appendix B: Infectious and post-infectious sequelae (disease states) 
 
Table S4: Overall proportion, symptom duration prior admission and hospitalization numbers used for the 
calculation of the disability-adjusted life years of melioidosis. 
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Uncertainty intervals for average durations were calculated using gamma distribution fitted to the mean and standard 
deviation, except for post infectious sequelae which were fitted to the remaining life expectancy. Whereas, for 
proportions, a beta-distribution was used based on number of cases and sample size.   
 
Abbreviations: DALY= disability-adjusted life years, sd= standard deviation and UI= uncertainty interval. 
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Appendix C: Risk factor contribution to melioidosis  
 
Table S5 Proportion of melioidosis cases with underlying co-morbidities.  
 
Comorbidity 
 
Proportion 
(95% UI) 
 
YLD  
(95% UI) 
 
YLD per 100.000 
(95% UI) 
DALY  
(95% UI) 
DALY per 100.000 
(95% UI) 
Diabetes 46·1%  
 (45·2-47·0) 
 23 304 
(10 490-45 111) 
0·42  
(0·191-0·820) 
2 137 433 
(1 459 182-3 046 177) 
 38·9 
(26·5-55·4) 
Chronic liver disease or 
alcohol abuse 
7·4% 
 (6·9-7·9) 
 3 755 
(1 688-7 284) 
0·068  
(0·031-0·132) 
344 449 
(233 462-493 074) 
 6·3 
(4·2-9·0) 
Chronic kidney disease 9·3%  
(8·8-9·8) 
 4 696 
(2 107-9 112) 
0·085 
(0·038-0·166) 
430 712 
(292 249-615 674) 
 7·8 
(5·3-11·2) 
Chronic lung disease 3·4% 
(3·0-3·7) 
 1 697 
(760-3 303) 
0·031 
(0·014-0·060) 
155 677 
(104 688-224 390) 
 2·8 
(1·9-4·1) 
 
Uncertainty intervals for comorbidity proportions were calculated using beta-distribution, based on the number 
presenting with comorbidity and sample size. 
Abbreviations: YLD=years lived with disability; DALY=disability-adjusted life years, sd=standard deviation, and 
UI=uncertainty interval. 
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Appendix D: GBD life expectancy estimates  
 
 
 
Country YLL  
(95% UI) 
YLL per 100·000   
(95% UI) 
YLD  
(95% UI)  
YLD per 100·000  
(95% UI) 
DALY  
(95% UI)  
DALY per 100·000  
(95% UI) 
African Region 675 169 (343 268-1 236 755) 73 (37-134) 5 817 (2 240-12 735) 0·631 (0·243-1·4) 680 986 (348 716-1 242 627) 74 (38-135) 
Angola 864 (52-2 816) 3·1 (0·188-10) 8·8 (0·590-31) 0·032 (0·002-0·111) 873 (61-2 826) 3·1 (0·219-10) 
Benin 25 580 (5 509-61 703) 242 (52-583) 241 (44-671) 2·3 (0·419-6·3) 25 820 (5 744-61 885) 244 (54-585) 
Burkina Faso 18 149 (2 422-49 711) 100 (13-274) 165 (20-509) 0·911 (0·112-2·8) 18 314 (2 583-49 834) 101 (14-275) 
Cameroon 15 229 (2 276-40 566) 67 (10·0-178) 141 (20-420) 0·616 (0·087-1·8) 15 370 (2 412-40 718) 67 (11-178) 
Central African Republic 3 928 (697-10 043) 86 (15-221) 33 (5·2-95) 0·725 (0·115-2·1) 3 961 (730-10 077) 87 (16-222) 
Chad 11 811 (1 275-33 978) 84 (9·1-243) 103 (10-331) 0·738 (0·074-2·4) 11 914 (1 380-34 097) 85 (9·8-243) 
Congo 7 278 (1 619-17 322) 146 (32-347) 68 (13-186) 1·4 (0·264-3·7) 7 345 (1 685-17 397) 147 (34-348) 
Côte d'Ivoire 31 979 (6 431-78 844) 138 (28-341) 264 (44-756) 1·1 (0·192-3·3) 32 243 (6 704-79 141) 140 (29-342) 
DRC 6 331 (673-18 312) 8·3 (0·883-24) 61 (6·2-197) 0·080 (0·008-0·258) 6 392 (733-18 388) 8·4 (0·962-24) 
Equatorial Guinea 170 (34-418) 14 (2·9-36) 1·4 (0·251-4·0) 0·121 (0·021-0·342) 172 (36-420) 15 (3·0-36) 
Eritrea 742 (52-2 354) 15 (1·1-49) 8·5 (0·686-29) 0·174 (0·014-0·589) 750 (60-2 365) 15 (1·2-49) 
Ethiopia 7 375 (767-21 525) 7·4 (0·768-22) 76 (8·0-242) 0·076 (0·008-0·243) 7 451 (837-21 615) 7·5 (0·838-22) 
Gabon 1 237 (281-2 926) 64 (15-152) 12 (2·2-33) 0·619 (0·112-1·7) 1 249 (293-2 941) 65 (15-152) 
Gambia 224 (5·5-828) 11 (0·278-42) 2·8 (0·151-10) 0·140 (0·008-0·518) 226 (8·1-831) 11 (0·412-42) 
Ghana 11 490 (1 165-33 607) 42 (4·2-122) 107 (9·7-352) 0·389 (0·035-1·3) 11 598 (1 271-33 742) 42 (4·6-122) 
Guinea 37 706 (7 736-92 247) 312 (64-763) 333 (61-928) 2·8 (0·502-7·7) 38 039 (8 067-92 570) 315 (67-766) 
Guinea-Bissau 2 908 (328-8 338) 164 (19-471) 26 (2·8-82) 1·5 (0·161-4·6) 2 935 (354-8 363) 166 (20-472) 
Kenya 2 795 (361-7 731) 5·9 (0·765-16) 29 (3·5-90) 0·061 (0·007-0·190) 2 824 (390-7 755) 6·0 (0·825-16) 
Liberia 12 397 (2 393-31 019) 276 (53-689) 111 (19-317) 2·5 (0·414-7·0) 12 507 (2 506-31 105) 278 (56-691) 
Madagascar 24 013 (5 117-57 931) 99 (21-239) 235 (43-657) 0·972 (0·179-2·7) 24 248 (5 339-58 180) 100 (22-240) 
Malawi 6 050 (1 085-15 471) 34 (6·2-88) 57 (9·4-163) 0·325 (0·054-0·929) 6 107 (1 142-15 533) 35 (6·5-88) 
Mali 16 849 (2 419-45 529) 96 (14-261) 151 (20-459) 0·863 (0·112-2·6) 16 999 (2 568-45 666) 97 (15-261) 
Mauritania 841 (65-2 623) 20 (1·6-63) 8·0 (0·572-28) 0·192 (0·014-0·661) 849 (73-2 631) 20 (1·7-63) 
Mauritius 88 (7·9-267) 7·0 (0·626-21) 2·4 (0·212-8·0) 0·190 (0·017-0·633) 91 (10-270) 7·2 (0·798-21) 
Mozambique 6 680 (845-18 564) 24 (3·0-66) 62 (7·7-192) 0·223 (0·028-0·686) 6 742 (910-18 622) 24 (3·2-66) 
Niger 10 656 (903-32 503) 54 (4·5-163) 103 (8·5-349) 0·520 (0·043-1·8) 10 759 (1 005-32 576) 54 (5·0-164) 
Nigeria 374 282 (78 458-909 318) 207 (43-502) 3 070 (551-8 590) 1·7 (0·304-4·7) 377 352 (81 303-912 324) 208 (45-504) 
Senegal 1 840 (103-6 077) 12 (0·689-41) 18 (1·1-65) 0·123 (0·008-0·435) 1 858 (121-6 101) 12 (0·807-41) 
Sierra Leone 16 790 (3 312-41 626) 232 (46-575) 132 (23-375) 1·8 (0·321-5·2) 16 922 (3 439-41 746) 234 (48-577) 
South Africa 751 (56-2 342) 1·4 (0·102-4·2) 8·2 (0·696-27) 0·015 (0·001-0·049) 759 (64-2 352) 1·4 (0·115-4·3) 
Table S6 Global disability-adjusted life years distribution with breakdown per country in 2015 using Global Burden Disease life expectancy  
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South Sudan 1 044 (105-3 054) 8·8 (0·884-26) 11 (1·2-35) 0·092 (0·010-0·292) 1 055 (116-3 064) 8·9 (0·974-26) 
Tanzania 8 389 (1 105-23 046) 16 (2·1-43) 86 (11-264) 0·159 (0·019-0·490) 8 475 (1 195-23 150) 16 (2·2-43) 
Togo 4 414 (652-11 830) 60 (8·8-160) 39 (5·1-119) 0·531 (0·069-1·6) 4 453 (693-11 868) 60 (9·3-160) 
Uganda 901 (32-3 167) 2·2 (0·081-7·9) 9·7 (0·477-36) 0·024 (0·001-0·090) 911 (42-3 177) 2·3 (0·104-7·9) 
Zambia 3 190 (369-9 084) 20 (2·3-56) 31 (3·6-96) 0·191 (0·022-0·595) 3 220 (399-9 115) 20 (2·5-57) 
Zimbabwe 202 (13-645) 1·3 (0·085-4·1) 2·2 (0·158-7·4) 0·014 (<0·001-0·047) 204 (15-647) 1·3 (0·098-4·1) 
American Region 62 317 (32 648-108 711) 11 (5·7-19) 1 291 (460-2 892) 0·225 (0·080-0·504) 63 608 (33 820-110 132) 11 (5·9-19) 
Argentina 515 (34-1 643) 1·2 (0·078-3·8) 11 (0·652-41) 0·026 (0·002-0·093) 526 (44-1 657) 1·2 (0·100-3·8) 
Bolivia 522 (45-1 574) 4·9 (0·416-15) 5·8 (0·479-19) 0·054 (0·004-0·182) 528 (50-1 579) 4·9 (0·466-15) 
Brazil 23 786 (3 520-63 372) 12 (1·7-31) 517 (64-1 598) 0·251 (0·031-0·776) 24 303 (3 965-63 987) 12 (1·9-31) 
Colombia 4 379 (661-11 614) 9·1 (1·4-24) 88 (12-267) 0·182 (0·024-0·554) 4 467 (745-11 710) 9·3 (1·5-24) 
Costa Rica 356 (64-901) 7·4 (1·3-19) 11 (1·6-32) 0·225 (0·033-0·666) 367 (74-913) 7·6 (1·5-19) 
Cuba 387 (19-1 298) 3·4 (0·165-11) 17 (0·791-62) 0·146 (0·007-0·542) 404 (32-1 315) 3·5 (0·278-11) 
El Salvador 2 918 (702-6 734) 46 (11-107) 59 (12-160) 0·934 (0·184-2·5) 2 977 (760-6 795) 47 (12-108) 
Guatemala 2 235 (404-5 642) 14 (2·5-35) 31 (4·7-90) 0·189 (0·029-0·553) 2 265 (436-5 674) 14 (2·7-35) 
Guyana 409 (78-1 017) 53 (10-132) 4·7 (0·675-14) 0·606 (0·088-1·8) 413 (83-1 022) 54 (11-133) 
Haiti 1 028 (81-3 170) 9·6 (0·758-30) 8·9 (0·804-29) 0·083 (0·008-0·274) 1 037 (90-3 179) 9·7 (0·841-30) 
Honduras 2 635 (362-7 149) 29 (4·0-80) 45 (6·2-136) 0·503 (0·069-1·5) 2 680 (406-7 197) 30 (4·5-80) 
Mexico 14 688 (2 467-37 874) 12 (2·0-30) 328 (45-987) 0·260 (0·036-0·784) 15 015 (2 762-38 244) 12 (2·2-30) 
Nicaragua 2 008 (346-5 135) 33 (5·7-84) 33 (4·8-98) 0·546 (0·079-1·6) 2 041 (378-5 175) 34 (6·2-85) 
Panama 1 816 (420-4 241) 46 (11-107) 38 (7·3-104) 0·954 (0·184-2·6) 1 854 (456-4 277) 47 (12-108) 
Paraguay 415 (11-1 521) 6·2 (0·161-23) 8·6 (0·358-32) 0·129 (0·005-0·486) 423 (18-1 529) 6·4 (0·273-23) 
Peru 1 117 (141-3 087) 3·6 (0·449-9·8) 22 (2·7-69) 0·070 (0·008-0·219) 1 139 (161-3 112) 3·6 (0·514-9·9) 
Suriname 400 (85-958) 72 (15-173) 6·6 (1·1-19) 1·2 (0·200-3·4) 406 (91-965) 73 (17-174) 
Venezuela  2 704 (487-6 841) 8·7 (1·6-22) 58 (8·6-170) 0·185 (0·028-0·546) 2 762 (542-6 902) 8·9 (1·7-22) 
Eastern Mediterranean 
Region  
15 713 (5 414-35 987) 3·7 (1·3-8·6) 101 (31-252) 0·024 (0·007-0·060) 15 814 (5 518-36 082) 3·8 (1·3-8·6) 
Iran 237 (8·1-835) 0·299 (0·010-1·1) 3·0 (0·106-11) 0·004 (<0·001-0·014) 240 (11-838) 0·303 (0·014-1·1) 
Iraq 479 (7·8-1 874) 1·3 (0·021-5·2) 3·4 (0·052-14) 0·010 (<0·001-0·040) 482 (11-1 878) 1·3 (0·031-5·2) 
Oman 71 (17-165) 1·7 (0·399-3·9) 1·1 (0·162-3·2) 0·026 (0·004-0·077) 72 (18-167) 1·7 (0·424-4·0) 
Pakistan 9 534 (722-29 494) 5·0 (0·381-16) 57 (4·3-190) 0·030 (0·002-0·100) 9 591 (775-29 572) 5·1 (0·409-16) 
Saudi Arabia 575 (55-1 696) 1·8 (0·175-5·4) 10·0 (0·858-33) 0·032 (0·003-0·104) 585 (64-1 708) 1·9 (0·202-5·4) 
Somalia 1 512 (142-4 490) 11 (1·0-32) 7·8 (0·726-25) 0·056 (0·005-0·181) 1 520 (149-4 499) 11 (1·1-32) 
Sudan 1 325 (81-4 271) 3·4 (0·209-11) 7·9 (0·515-27) 0·020 (0·001-0·070) 1 333 (88-4 279) 3·4 (0·228-11) 
Yemen 1 979 (339-5 054) 7·4 (1·3-19) 11 (1·6-31) 0·040 (0·006-0·115) 1 990 (350-5 065) 7·4 (1·3-19) 
South-east Asian Region 2 618 321 (1 451 689-4 256 437) 138 (76-224) 30 640 (12 500-62 865) 1·6 (0·658-3·3) 2 648 960 (1 480 429-4 286 603) 139 (78-226) 
Bangladesh 415 343 (142 696-831 078) 258 (89-516) 4 974 (1 366-11 993) 3·1 (0·848-7·4) 420 317 (147 071-836 268) 261 (91-519) 
Bhutan 381 (77-926) 48 (9·7-118) 3·8 (0·552-11) 0·487 (0·070-1·4) 385 (80-930) 49 (10-118) 
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India 1 393 679 (432 258-2 912 344) 106 (33-222) 13 518 (3 390-33 836) 1·0 (0·259-2·6) 1 407 197 (445 480-2 925 456) 107 (34-223) 
Indonesia 468 604 (117 143-1 064 654) 182 (45-412) 6 147 (1 297-16 220) 2·4 (0·503-6·3) 474 751 (122 945-1 070 956) 184 (48-415) 
Myanmar 164 733 (45 906-358 681) 314 (88-684) 1 596 (372-4 086) 3·0 (0·710-7·8) 166 329 (47 382-360 422) 317 (90-688) 
Nepal 22 710 (5 408-52 402) 79 (19-183) 259 (54-690) 0·903 (0·189-2·4) 22 968 (5 668-52 666) 80 (20-184) 
Sri Lanka 27 004 (7 796-58 001) 130 (38-280) 834 (196-2 159) 4·0 (0·946-10) 27 839 (8 589-58 923) 134 (41-284) 
Thailand 125 564 (40 893-257 155) 183 (60-375) 3 305 (848-8 261) 4·8 (1·2-12) 128 870 (44 116-260 432) 188 (64-379) 
Timor-Leste 302 (35-849) 24 (2·9-68) 2·8 (0·307-8·7) 0·225 (0·025-0·703) 305 (38-852) 25 (3·1-69) 
West-Pacific Region 671 048 (404 144-1 029 387) 40 (24-61) 12 693 (5 185-26 073) 0·754 (0·308-1·5) 683 741 (416 769-1 042 312) 41 (25-62) 
Australia 1 746 (400-4 083) 7·3 (1·7-17) 99 (19-276) 0·417 (0·078-1·2) 1 846 (486-4 195) 7·8 (2·0-18) 
Brunei Darussalam 428 (141-872) 102 (34-209) 15 (3·5-38) 3·6 (0·835-9·2) 443 (156-888) 106 (37-213) 
Cambodia 56 637 (14 794-126 210) 365 (95-813) 654 (141-1 723) 4·2 (0·909-11) 57 291 (15 475-126 878) 369 (100-818) 
China 121 635 (42 238-242 450) 8·7 (3·0-17) 3 226 (880-7 859) 0·231 (0·063-0·563) 124 861 (45 453-245 661) 8·9 (3·3-18) 
Fiji 92 (12-252) 10 (1·3-28) 1·6 (0·163-5·1) 0·180 (0·018-0·574) 93 (13-254) 10 (1·5-28) 
Laos 12 505 (3 560-27 011) 188 (53-405) 112 (25-291) 1·7 (0·382-4·4) 12 617 (3 669-27 117) 189 (55-407) 
Malaysia 25 409 (6 814-56 128) 83 (22-183) 912 (195-2 431) 3·0 (0·635-7·9) 26 321 (7 584-57 130) 86 (25-186) 
Papua New Guinea 3 834 (888-8 934) 48 (11-113) 33 (6·7-89) 0·421 (0·084-1·1) 3 868 (920-8 961) 49 (12-113) 
Philippines 214 037 (84 580-402 442) 210 (83-396) 2 976 (934-6 893) 2·9 (0·918-6·8) 217 012 (87 539-405 440) 213 (86-399) 
Singapore 2 498 (253-7 265) 45 (4·6-131) 202 (22-633) 3·6 (0·406-11) 2 700 (420-7 477) 49 (7·6-135) 
Vietnam 232 227 (58 497-526 753) 248 (63-563) 4 462 (940-11 849) 4·8 (1·0-13) 236 689 (62 704-531 692) 253 (67-568) 
GLOBAL 4 042 568 (2 740 388-5 775 291) 74 (50-105) 50 542 (22 778-97 825) 0·919 (0·414-1·8) 4 093 110 (2 790 743-5 826 117) 74 (51-106) 
 
 
Abbreviations: DRC= Democratic Republic of Congo; UI= uncertainty interval; YLL= years life lost; YLD= years lived with disability and DALY= disability-adjusted life years· 
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Appendix E: SDI and HAQ results 
 
Figure S6: Healthcare Access and Quality Index (A) and Socio-demographic Index (B) per country versus 
disability-adjusted life years  
 
A 
 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: AFR= African region; AMR= American region; EMR= Eastern Mediterranean region, SEAR= South-
east Asian region, WPR= West-Pacific region; and DALYs= disability-adjusted life years. 
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Table S7 Healthcare Access and Quality Index and Socio-demographic Index per country  
 
Country HAQ SDI 
African Region     
Angola 40·7 0·419 
Benin 43·0 0·345 
Burkina Faso 42·9 0·237 
Cameroon 44·4 0·464 
Central African Republic 28·6 0·282 
Chad 37·7 0·287 
Congo 43·5 0·527 
Côte d'Ivoire 42·4 0·381 
DRC 40·4 0·239 
Equatorial Guinea 48·4 0·609 
Eritrea 38·1 0·324 
Ethiopia 44·2 0·302 
Gabon 51·4 0·644 
Gambia 49·7 0·327 
Ghana 49·7 0·511 
Guinea 38·6 0·278 
Guinea-Bissau 36·3 0·294 
Kenya 48·7 0·472 
Liberia 45·4 0·283 
Madagascar 43·7 0·370 
Malawi 47·0 0·309 
Mali 45·6 0·231 
Mauritania 52·0 0·401 
Mauritius 65·7 0·735 
Mozambique 43·0 0·278 
Niger 41·0 0·146 
Nigeria 51·3 0·474 
Senegal 44·4 0·334 
Sierra Leone 41·3 0·323 
South Africa 52·0 0·716 
South Sudan 38·8 0·262 
Tanzania 49·9 0·411 
Togo 44·3 0·362 
Uganda 42·9 0·377 
Zambia 41·6 0·467 
Zimbabwe 48·7 0·538 
American Region   
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Argentina 68·4 0·772 
Bolivia  59·2 0·612 
Brazil 64·9 0·662 
Colombia 67·8 0·700 
Costa Rica 72·9 0·723 
Cuba 73·5 0·766 
El Salvador 64·4 0·619 
Guatemala 55·7 0·543 
Guyana 49·8 0·655 
Haiti 38·5 0·412 
Honduras 53·9 0·568 
Mexico 62·6 0·718 
Nicaragua 64·3 0·563 
Panama 64·4 0·747 
Paraguay 60·4 0·644 
Peru 69·6 0·705 
Suriname 56·7 0·704 
Venezuela  64·7 0·728 
Eastern Mediterranean Region     
Iran 71·1 0·715 
Iraq 60·1 0·576 
Oman 77·1 0·730 
Pakistan 43·1 0·468 
Saudi Arabia 79·4 0·759 
Somalia 34·2 0·151 
Sudan 50·1 0·428 
Yemen 49·6 0·408 
South-east Asian Region   
 
Bangladesh 51·7 0·472 
Bhutan 52·7 0·532 
India 44·8 0·556 
Indonesia 49·2 0·652 
Myanmar 48·4 0·520 
Nepal 50·8 0·423 
Sri Lanka 72·8 0·705 
Thailand 70·8 0·705 
Timor-Leste 51·6 0·450 
West-Pacific Region   
 
Australia 89·8 0·915 
Brunei Darussalam 70·0 0·923 
Cambodia 50·7 0·486 
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China 74·2 0·678 
Fiji 46·6 0·693 
Lao 44·9 0·508 
Malaysia 66·6 0·767 
Papua New Guinea 38·6 0·448 
Philippines 52·0 0·645 
Singapore 86·3 0·881 
Vietnam 66·3 0·628 
 
 
Abbreviations: DRC= Democratic Republic of Congo; DALYs= disability-adjusted life years; SDI=Socio-
demographic Index; HAQ= Healthcare Access and Quality.   
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Appendix F: Global burden of a select neglected and emerging/re-emerging tropical diseases 
and corresponding investments in research and development 
 
Figure S7: Global burden of a selection of neglected and emerging/re-emerging tropical diseases and 
corresponding investments in research and development 
 
 
 
 
 
Leptospirosis is not officially recognized as a neglected tropical disease. Recognized neglected tropical diseases (by 
WHO) and leptospirosis are depicted in blue and melioidosis in red. 
Abbreviations: DALYs= disability-adjusted life years and WHO= World Health Organization.  
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Table S8: Global burden of melioidosis and selected neglected tropical diseases. 
 
Neglected tropical diseases WHO DALY in million 
(2015) 
Global Investment by disease in million $ 
(2016) 
Intestinal Nematode Infections 4·56 283 M 
Leishmaniasis 1·06 516M 
Schistosomiasis 2·63 244M 
Lymphatic Filariasis 1·24 146M 
Food-borne Trematodiases 1·09 105M 
Rabies 1·63 <4M 
Dengue 2·86 788M 
African Trypanosomiasis 0·20 400M 
Chagas Disease 0·24 221M 
Cysticercosis 1·96 24M 
Onchocerciasis 0·99 103M 
Trachoma 0·24 23M 
Echinococcosis 0·69 <4M 
Yellow Fever 0·63 <4M 
Leprosy 0·42 109M 
Leptospirosisa  2·90 5M 
Melioidosisa 4·64  <4M 
 
All investments by disease in millions of $ are from the WHO.16 All WHO DALY estimates are from the WHO16 
except leptospirosis from Torgerson et al.17 Infectious diseases not represented in the top 39 in terms of research and 
development, were assigned <4M, corresponding to the global investment of the last of the 39. Abbreviations: WHO= 
World Health Organization and DALY = disability-adjusted life years. 
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Appendix G: Bibliographic details of references containing information for estimation of the 
global burden of melioidosis 
 
*References of included studies are attached as necessary additional data (word document). Will be 
live with publication on refworks.com.  
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Appendix H: R code 
 
All code and results are now available on github: https://github.com/brechtdv/melioidosis 
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